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Abstract
Throughout nature, many proteins provide a specific function in response to
some input signal (e.g., phosyphorylation, pH, etc.), a process that is oftentimes
described as switching a protein “on” or “off.” The advent of protein engineering has
allowed for the creation and understanding of chimeric proteins for uses in a number of
applications such as therapeutics, biosensors and energy production. Two proteins,
hemagglutinin (HA) of fowl plague influenza virus and a chimeric protein comprising a
fusion between the LFA-1 I domain and the EF3 and EF4 hands of calmodulin, have
been investigated in this dissertation. Both of these proteins undergo structural
rearrangements in response to an input signal in a process that could be described as
molecular switching.
Hemagglutinin (HA) is a viral fusion protein that undergoes an irreversible
conformational change upon acidification to catalyze the fusion of endosomal and viral
membranes. Directed evolution was previously used to identify novel mutants with
activation pH across a range of 4.8 – 6.0; wild-type HA activates around pH 5.2.
Examination of library mutants has enabled us to identify individual amino acids
responsible for phenotypic changes and thus provides additional structure-function
insight highlighting the importance of HA1 headgroups in pH sensing.
Secondly, we have improved a previously created chimeric protein switch using
the integrin LFA-1 I domain and the EF3 and EF4 hands of calmodulin; the original
switch protein had a 2.4-fold increase for the I domain ligand, ICAM-1, in the presence
of a calmodulin target peptide. Directed evolution has revealed a mutant switch with an
additional twenty-fold increase in ICAM-1 binding in the presence of peptide.
Additionally, the specificity of the chimeric protein for the original peptide sequence has
been engineered, creating a new switch that responds to a different peptide sequence
rendering the original peptide nonfunctional. Both proteins, hemagglutinin and the I
v

domain-calmodulin fusion, represent the importance of conformational changes in
controlling protein function. The ability to manipulate these changes underscores the
power of protein engineering and directed evolution and can lead to the development of
complex biomolecules that can be used in a variety of applications.
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Chapter 1 : Introduction
1.1 Background
Nature is beautifully complex with a multitude of processes, proteins, and
interactions to inspire new ideas for the creation of technologies to fight diseases and to
better understand the mechanisms behind them. Characterizing, understanding, and
engineering different proteins can lead to the development of smarter materials to be
used for different applications such as targeted drug delivery, biosensing, and molecular
imaging.
The unique sequence of amino acids that defines a specific protein heavily
influences the three-dimensional structure, or shape, of the protein.

Myoglobin, an

iron- and oxygen-binding protein found in many animal cells, was the first protein to
have its three-dimensional structure solved in 1958.1 Since 1958, the number of protein
structures that have been determined has grown exponentially such that the Protein
Data Bank now contains close to 88,000 protein structures (www.rcsb.org). It is this
three-dimensional structure that is key in determining the function of a protein.
Antibodies have a distinct Y-shape, consisting of two variable regions and an Fc
domain, which is critical to the immunological function of the protein. Variable domains,
which contain the antigen binding site, have extreme sequence diversity allowing
antibodies to bind foreign antigens with great specificity. Conversely, the Fc domain is
composed of highly conserved sequences and has receptor binding cites for
engagement with cells of the immune system.2 Other proteins, such as hemoglobin can
have flexible structures that provide the basis for their function.3; 4 As one oxygen
molecule binds to a heme in one of the hemoglobin subunits, strains in the protein
caused by the location of the hemes are relaxed allowing the protein to change its
shape to allow for better positioning of the hemes and thus allowing oxygen to bind with
higher affinity.5 It is the intrinsic ability of proteins like hemoglobin to change, or switch,
1

their shape that led to the understanding of allostery and serves as a fundamental
principle in this dissertation.
1.1.1 Allostery
Protein structure and conformational flexibility play a critical role in controlling
protein function. A number of different types of proteins exploit structural
rearrangements to carry out their respective functions such as enzymes, chaperonins,
membrane fusion proteins and intergrins.6; 7; 8; 9 The conformational changes of a
protein often occur in response to effector molecules (metabolites, ATP, DNA, RNA,
peptides, etc.) that bind at sites distinct from the active site resulting in a reversible
conformational change in the three dimensional structure of the protein, a mechanism
known as allostery.10 In the seminal paper first describing protein allostery, Monod and
colleagues describe a number of enzymes that are allosterically regulated, such as
ATCase and threonine-deaminase.10 GroEL, a molecular chaperone that assists in the
folding of nonnative polypeptides, performs an intricate array of allosteric movements
choreographed by cooperative ATP binding. 7 Integrins, which will be discussed in
more detail below, also undergo drastic conformational refolding in response to
intracellular signals in order to adopt a high affinity conformation and assist in leukocyte
firm adhesion.9; 11 The integrin, lymphocyte function-associated antigen-1 (LFA-1,
integrin αLβ2) is able to firmly adhere to sites of inflammation by high affinity binding
through its inserted (I) domain. The affinity of αL I domain for its ligand, ICAM-1, is
allosterically regulated in response to the reversible „pulling‟ of its α7 helix which causes
a series of rearrangements within the domain resulting in a high affinity state.
However, not all conformational rearrangements are reversible. For instance,
viral fusion proteins, such as HIV-1 GP120/41 and hemagglutinin (HA), expressed on
the surface of enveloped viruses mediate the merging of two biological membranes and
undergo irreversible conformational changes in response to ligand binding or lowered
2

pH, respectively.12 The viral fusion protein, gp120/41, is expressed on the surface of
HIV-1 and effects entry of the virus into the cell. It is structurally similar to influenza
hemagglutinin, which will be discussed in detail below, as both proteins are processed
as fusion incompetent polypeptides (HIV-1 GP160 and influenza HA0) and are
subsequently proteolytically cleaved into a fusion competent molecule. Upon exposure
to an activating stimulus (CD4 binding for gp120/41 and low pH for HA) the fusion
proteins undergo an irreversible conformational switch to an extended, stable coiled coil
conformation exposing their fusion proteins (N-termini of gp41 and HA2, respectively) to
the target membrane.12; 13 Insertion of the fusion peptides followed by refolding of the
fusion proteins brings the two membranes in close proximity to each other allowing
them to merge.
Allosteric rearrangements and large-scale conformational refolding can be
thought of as a protein switching mechanism. In other words, due to an external input a
protein can be forced to switch conformations. This dissertation will explore this
concept of protein switching by characterizing the viral fusion protein, hemagglutinin,
and exploiting the concept of allostery, using the I domain of the LFA-1 integrin and the
EF3 and EF4 hands of calmodulin to engineer a chimeric fusion protein switch. In the
case of αL I domain, conformational switching will be shown to be induced by the
binding of an exogenous peptide and hemagglutinin mutations will be identified that
point to a hotspot within the protein structure that likely controls its switching
mechanism.
1.1.2 Protein switches
Different design motifs have been used to engineer a number of different protein
switches. Common design motifs for engineering protein switches include protein
splitting, domain insertion, mutually exclusive folding and domain swapping.14; 15 Most
switches rely on using enzymes or reporter proteins, such as luciferase, GFP, β3

lactamase, or dihydrofolate reductase (DHFR) as the output domain to provide an easily
readable signal upon activation by the input domain.14; 15 An early example of an
engineered switch involved domain insertion of calmodulin into a circularly permuted
GFP. Upon the addition of calcium, the GFP-calmodulin switch demonstrated about an
8-fold enhancement in fluorescence.16 β-lactamase (BLA) has been routinely used in
protein switch construction as hydrolysis of beta-lactam antibiotics makes screening
mutants very efficient. Domain insertions with BLA to control substrate hydrolysis
include the maltose binding protein (MBP), calmodulin (CaM), and a short hexapeptide
to engineer a metal ion binding site.17; 18; 19 Mutually exclusive folding is another design
motif in engineering protein switches where the folding of one protein causes the
unfolding of its fusion partner. A fusion where human ubiquitin is inserted into an
exposed loop of B. amyloliquefaciens barnase showed that by controlling barnase
folding via ubiquitin, cell viability could be regulated.20 Regardless of the design
method chosen, controlling protein function by an input domain provides an additional
level of regulation.
1.1.3 Possible applications of engineered switches
A large number of devastating illnesses are either virally induced (e.g. HIV/AIDS,
T-cell leukemia)21 or are associated with chronic inflammation (e.g. rheumatoid arthritis,
Crohn‟s disease, psoriasis)22. Both proteins that will be studied in this thesis are either
heavily involved in inflammatory responses - I domain - or from the same family of
proteins responsible for seasonal flues - hemagglutinin - that also share many structural
and functional properties with retroviral proteins such as the HIV fusion protein
gp120/41. Therefore, these proteins serve as convenient starting points for the
development of target specific molecules.
Site-specific imaging or drug delivery is a complicated problem with a number of
factors such as particle size, circulation half-life, immunogenicity, and target specificity
4

that need to be considered.23; 24 Recently, the αL I domain has been conjugated to the
surface of nanoparticles for targeted delivery of drug and gene therapies to cells over
expressing ICAM-1 both in vitro and in vivo.25; 26; 27 These molecules use previously
engineered high affinity I domain28 to selectively target ICAM-1 making these
nanoparticles highly efficient at targeting tumors where drug delivery by the permeability
and retention (EPR) effect is less efficient. Designing a protein switch where I domain
affinity is regulated by the presence of exogenous peptide would provide an additional
layer of specificity in targeted imaging and delivery systems. Further engineering of
peptide specificity would enhance the targeting capabilities.
Characterization and understanding of hemagglutinin and what leads to its
conformational switching could lend insight into similar proteins‟ (e.g., HIV-1 gp120/41)
modes of action therefore leading to more effective retroviral drugs. The fusion peptide
of HA2 has also been shown to be effective in promoting fusion between a liposome
and cellular membranes as an efficient means of delivering genetic material to a cell. 29;
30

A better understanding of HA allows for possible engineering of ligand binding sites

into locations of the hemagglutinin that are critical in pH sensing. Grafting in a ligand
binding site in a pH sensing „hot spot‟ could allow for controlled release of drugs
encapsulated in liposomes by the presence or absence of a ligand, providing more
control over current approaches where only the fusion peptide of hemagglutinin is used
to assist in liposome-membrane fusion. One concern about an approach of this nature
would be immune responses due to the presence of a viral protein.
Development of a protein switch, along with the ability to alter ligand specificity,
would demonstrate the profound ability to build a biomolecule that could do almost
anything; possibilities include selectively delivering a drug to a specific target or
developing a biosensor for security or safety purposes. An engineered protein switch
could be used to benefit society in a nearly unlimited number of ways.
5

Chapter 2 : Characterization of hemagglutinin mutants for
identification of novel pH sensing mutations
2.1 Introduction
Membrane fusion is a highly evolved process that accounts for many biological
activities including cell-cell fusion (e.g. sperm and oocyte), extra- and intra-cellular
fusion of pathogens with host cells (enveloped viruses), or intracellular fusion of
organelles.8 The process by which the influenza viral membrane fuses with a cellular
endosomal membrane, via the viral fusion protein hemagglutinin (HA), to release its
viral RNA within the host cell is a highly studied, model fusion event.8; 12; 31; 32 Following
receptor binding, internalization of the virus by endocytosis leaves the viral genome
separated from the cell cytoplasm by two membranes, endosomal and viral. Fusion of
these two membranes is energetically unfavorable without the additional energy
released by HA upon its irreversible, conformational change in response to the lowered
pH of the acidified endosome.33; 34
2.1.1 Hemagglutinin
The typical membrane fusion pathway involves four intermediate states that
include 1) the close contact of the opposing membranes, 2) destabilization of the
membranes, 3) a hemifusion state and 4) finally the complete fusion pore

8; 33

. Many

mechanisms of action can lead to membrane fusion but a well characterized pathway
involves fusion proteins, such as hemagglutinin (HA) (Figure 2. 1). A better
understanding of membrane fusion, and in particular, the action of hemagglutinin can
lead to the design of better smart molecules for such practices as targeted drug or gene
delivery and to the design of novel viral inhibitors.

6
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Intermediate
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Hemifusion

Fusion pore
(post-fusion)

Figure 2. 1 Proposed role of HA in membrane fusion. HA1 is not shown for clarity. At
acidic pH, HA refolds to expose its fusion peptide to the target membrane (1). Trimers
aggregate quickly, followed by a second refolding step at the C-terminal end of HA2
where the kink region (purple) undergoes a helix-to-loop transition (3 and 4). The
refolding of the C-terminal end brings the two apposing membranes into close proximity
allowing for the formation of a transitive hemifusion state (5). The transmembrane
domains and fusion peptides of HA are brought together allowing for pore formation (6).
Figure 2.1 from Gruenke, J.A., Armstrong, R.T., Newcomb, W.W., et. al.: New Insights
into the Spring-Loaded Conformational Change Influenza Virus Hemagglutinin. J. Virol.
(2002), 76(9): 4456-4466 originally published by BioMed Central.35
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Hemagglutinin is a membrane glycoprotein composed of three identical
heterodimer subunits, HA1 and HA2 (Figure 2.2 A). The HA1 subunit is approximately
330 amino acids in length and extends 96 Å from its amino-terminal end near the viral
membrane distally into a globular head domain composed of an 8-stranded β-sheet
structure, which contains the binding pocket for sialic acid.36 The carboxy-terminal
region of the polypeptide extends 60Å back toward the viral membrane anti-parallel to
the amino-terminal region of HA1.36 The HA2 subunit is approximately 220 amino acids
composed of a short alpha helix (29Å) connected by an extended chain to a long α-helix
(76Å) followed by a transmembrane domain and short cytoplasmic tail.36; 37 The
extended loop of HA2 connecting the two helices, referred to as the B-loop, undergoes
a loop-to-helix transition to extend the coiled-coil structure of the protein which relocates
the fusion peptide more than 100 Å from its buried position in the neutral pH
conformation towards the target membrane(Figure 2.2 A).12; 38; 39 Each subunit is
synthesized as a single polypeptide chain (HA0) and trimerizes in the endoplasmic
reticulum.40 The trimers are immediately transported to the Golgi complex where the
HA0 subunits are cleaved by either a subtilisin-like (polyarginine H5 and H7 subtypes)
or trypsin-like (all other subtypes are monoarginine) protease either in the trans-Golgi or
in the plasma membrane region39; 41. Cleavage of HA0 into the disulfide-linked
HA1/HA2 subunits results in the newly formed N-terminal residues of HA2, known as
the fusion peptide, burying into a cavity of ionizable residues of the trimeric coiled-coil
(Figure 2.2 B).32; 42 The ectodomain of HA is stabilized by a number of intramolecular
interactions consisting of intra-domain and -subunit disulfide bonds, polar and
hydrophobic interactions between adjacent α-helices,36 and a number of single and
complex salt bridges.43
Hemagglutinin binds to sialyted cell-surface receptors where the enveloped virus
is endocytosed. The lowered pH of the endosome causes an irreversible
conformational change in the hemagglutinin structure leading to fusion of the viral and
8

Figure 2.2 Influenza hemagglutinin. A) Trimer of hemagglutinin monomers showing
three major structures on the pathway towards low pH refolding where the HA1 subunit
is shaded blue, HA2 is red and the N-terminal HA2 fusion peptide is yellow. Left panel
and (B), HA is synthesized as a single polypeptide chain HA0 before proteolytic
cleavage resulting in a disulfide-linked HA1/HA2. Middle panel, following cleavage of
HA0 the newly formed fusion peptide imbeds itself into the trimeric coiled-coil. Right
panel, under acidic conditions the protein undergoes an irreversible conformational
change that results in the dissociation of HA1 headgroups (not shown) and relocates
the fusion peptide more 100 Å towards the target membrane. B) Left and middle
panels, rearrangement of the fusion peptide. The black sphere represents the Nterminal glycine of the newly formed HA2 subunit. Right panel, the kink angle of the
fusion peptide which is essential for insertion into the target membrane as it allows the
more hydrophobic N-terminal half of the peptide to associate with the hydrophobic
bilayer while the C-terminal half is more exposed to a hydrophilic environment. Figure
2.2 A and B reprinted from Cross, K.J., Langley, W.A., Russell, R.J., Skehel, J.J., and
D.A. Steinhauer. Compositions and Functions of the Influenza Fusion Peptide. Protein
and Peptide Letters (2009), 16: 766-778, with permission from Bentham Science
Publishers.44
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Figure 2.2 Continued
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endosomal membranes. Protonation of charged residues in both the HA1 head group 45
and fusion peptide pocket46; 47 are disrupted resulting in the HA1 head groups
dissociating and allowing the fusion peptide to be exposed to the target membrane.
The fusion peptide is composed of two short helices, the N-terminal helix consisting of
conserved hydrophobic and glycine residues and the C-terminal half that is amphipathic
with a number of charged and polar residues, that adopts a kink angle in the center of
the helix of approximately 105° (Figure 2.2 B).48; 31; 49; 50 The mechanism of membrane
fusion mediated by the viral fusion peptide remains unclear (i.e., whether the fusion
peptide inserts into the endosomal membrane or the viral membrane, reviewed in ref. 8).
Most current structural data suggest that the fusion peptide is extruded from its
hydrophobic cavity in the coiled coil structure and extended towards the target
membrane (e.g., the endosomal membrane) where it inserts. Rearrangements occur at
the membrane proximal end of HA2 causing the C-terminal part of the helix to break
and fold back upon itself bringing the fusion peptide and transmembrane domains into
close proximity, and thus the apposed membranes44; 46; 51. The membrane defects
imposed by the fusion peptide and the negative curvature of the membrane during the
refolding of HA are predicted to lower the energetic barrier to allow fusion to proceed
(Figure 2. 1).
While the precise mechanism of hemagglutinin-mediated membrane fusion is not
explicitly understood, there is agreement in the literature as to some necessary steps on
the pathway toward membrane fusion. First, at least eight HA trimers rapidly aggregate
at the site of fusion in a non-rate limiting step, of which only two or three are needed to
refold to promote fusion.52; 53 White and colleagues demonstrated that viral membrane
fusion is a cooperative process that involves the concerted action of at least three
timers, which has also been verified through single-particle kinetic experiments.54; 55
This cooperativity is likely responsible for an autocatalytic activation phenomenon
employed by HA. It is well understood that hemagglutinin aggregates at the site of
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membrane fusion and that this clustering often occurs in “lipid raft” microdomains.56
These clusters of HA coincide neatly with the idea of synchronized activation proposed
by Markovic and colleagues. The authors suggest that adjacent HA proteins at high
local densities will undergo a synchronized conformational change to effectively lower
the energy barrier separating the metastable conformation from the final low-energy
conformation, ensuring that the virus will efficiently carry out the membrane fusion
process.57 Likewise, Lee, Goulian and Boder also described a cell-scale autocatalysis
mechanism where only two states, activated or inactivated HA, exist. Data show that
freshly expressed protein can be activated by the presence of previously refolded HA
implying a feedback autocatalysis mechanism.58
2.1.2 Spring-loaded model of HA
The structural transitions that lead to the final irreversible HA conformation have
been well characterized with crystal structures depicting each of the important
intermediate structures. As mentioned earlier, HA is processed as a single polypeptide,
HA0, which is thermodynamically stable and unable to undergo the irreversible
conformational change at low pH. Proteolytic cleavage of HA0 results in disulfide-linked
HA1 and HA2 subunits and the repositioning of the 20 N-terminal amino acids of HA2,
the fusion peptide, into a hydrophobic cavity within the HA trimer. This structure is
considered to be trapped in a metastable state at neutral pH and readily refolds to a
lower energy conformation at low pH or at neutral pH with the addition of a denaturant.59
The lowest energy conformation of HA occurs at the pH of fusion where the B-loop has
undergone a loop-to-helix transition resulting in a HA trimer that is stabilized by an
extended coiled coil structure. The transition from the metastable neutral pH structure
to the stable low pH structure is supported by the spring-loaded model for HA
refolding.38; 59
The spring-loaded model for hemagglutinin refolding is as follows:
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Proteolytic cleavage of HA0 results in a metastable structure of HA that is
primed for refolding
HA1 headgroups act as clamps preventing the B-loop of HA2 to undergo
its loop-to-helix transition
Dissociation of HA1 headgroups likely precedes the loop-to-helix transition
The loop-to-helix transition results in the formation of an extended coiled
coil structure, a lower energy conformation
Before the low pH structure of HA was solved, the residues composing the Bloop of HA2 were shown to adopt a helical structure at low pH in solution.38 This
indicated that the B-loop of HA2 prefers a helical conformation but is blocked from
refolding by the HA1 headgroups. Studies have expanded upon the importance of the
B-loop transition by introducing mutations to stabilize this loop and prevent HA refolding
into an extended coiled coil structure. Mutation of H2 HA2 R106H stabilizes the trimer
well below the pH of fusion for wild-type H2 HA.60 Crystal structures of this mutant at
neutral and low pH indicate that side chain interactions between the loop and the long α
helix of HA2 are lessened at low pH, evidence of a possible early intermediate in the
spring-loaded mechanism.60 A double proline HA mutant, F63P/F70P (H3 HA2
numbering), resulted in a fusion incompetent protein whose coiled coil structure was
interrupted by the proline substitutions following irreversible low pH refolding. 35 It was
argued that while the double mutant refolded at low pH, the proline mutations effectively
shortened the coiled coil structure preventing the necessary tension needed for
membrane fusion to occur indicating that the loop-to-helix transition is a necessary
component of the spring-loaded model.35 Intersubunit disulfides engineered to prevent
the HA1 headgroups from dissociating at low pH abolished HA refolding and membrane
fusion indicating the likely necessity of HA1 headgroup dissociation in HA refolding.61; 62
Finally, targeted molecular dynamics using neutral and low pH crystal structures (1HGF
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and 1HTM, respectively) indicated that the spring-loaded conformational mechanism is
the most energetically favorable pathway between the structures.63
A number of studies have examined mutations throughout the structure of HA to
identify pH sensing mutations and their effect on HA refolding.64; 65 These studies
genereally relied upon sequence analysis and/or structural information to identify
residues or parts of the structure to target for identification of pH sensing residues.
Previous work in our lab developed a flow cytometry assay that decouples HA refolding
from membrane fusion.58 This assay was then used in a directed evolution experiment
to generate HA mutants whose structures are either stabilized or destabilized with
respected to wild-type H7 HA. We have analyzed the different mutations that came from
this previous directed evolution work in order to try and identify individual mutations that
are responsible for pH sensing and to gain further insight into the structure-function
relationship of HA. Analysis of individual mutations mapped the majority of the changes
to the HA1 domain, and more specifically to the interface of two HA1 subunits. While
there is agreement in the literature that some loosening of the HA1 domains precedes
the large structural rearrangements leading to the fusion competent structure of HA, our
data suggest that HA1 plays a more significant role in controlling HA refolding.
2.2 Materials and Methods
2.2.1 DNA, library and point-mutant construction
Kozak sequence GCCACC was added to the wild-type FPV HA gene51 (from
A/FPV/Rostock/34) by PCR in order to increase the expression in mammalian cells.
Amino acid residues HA2 11-20 (i.e. fusion peptide residues 11–20) were replaced with
the c-myc epitope tag sequence via PCR, and referred to as HA3.1, as previously
described.58 HA3.1 DNA was randomly mutated by non-biased error-prone PCR using
Mutazyme II polymerase (Stratagene, Santa Clara, CA). PCR products were purified by
electroelution and digested with Xho I and Not I. They were then ligated into pLNCX2
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retroviral expression vector (Clontech, Mountain View, CA). E.coli transformation was
done by electroporation and the cells were cultured in 250 ml LB Amp medium in a 37
°C shaker for 36 hours. The library size was determined by plating 20 ul of the culture
after 36 hours of incubation and counting the number of colonies on the plate after a 20
hour incubation at 37 °C. The number of colonies was then multiplied by 20,000. Point
mutants were created by site-directed mutagenesis using the QuikChange II XL kit
(Stratagene) following the manufacturer‟s protocol. Primers were created with a
minimum of 15 nucleotides of homology on either side of the desired amino acid
change. Point mutants were confirmed by sequencing prior to retroviral transduction of
the point mutant to create a stably-expressing HA with the mutation.
2.2.2 Cell culture
All mammalian cell cultures were maintained at 37°C and 5% CO2. NIH-3T3
cells (a gift from Dr. John Crocker, University of Pennsylvania), EcoPack2-293 and
AmphoPack-293 (Clontech, Mountain View, CA) were grown in Dulbecco‟s Modified
Eagles Medium (DMEM) (Hyclone, Logan, UT) supplemented with 10% (v/v) fetal
bovine serum (Hyclone), 100 U/ml penicillin and 100 ug/ml streptomycin (Life
Technologies, Grand Island, NY). EcoPack2-293 and AmphoPack-293 are HEK293
derived cell lines stably expressing viral structural genes gag, pol and env for safe
production of infectious, replication-incompetent virions. Media was replaced roughly
every 48 hours and cultures were passaged prior to reaching confluency (~4 days).
During passaging, cells were washed with Dulbecco‟s phosphate buffered saline
(DPBS) containing 8 g/L NaCl, 200 mg/L KCl, 1150 mg/L Na2HPO4, 200 mg/L KH2PO4.
The cell monolayers were then detached using either 0.25% trypsin-EDTA (routine
passage) or 0.05% trypsin-EDTA (for analysis).
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2.2.3 Retroviral expression and viral titer determination
1×106 EcoPack 2-293 (BD Biosciences, Mountain View, CA) packaging cells
were plated in each well in a 6-well plate 16-20 hours before transfection, and
transfected with 10 μg of retroviral expression vector library. Virus containing medium
was collected at either 24 hours or 48 hours post-transfection and filtered through a
0.45 μm cellulose acetate filter. NIH-3T3 cells were plated 24 hours prior to infection in
6-well plates at a density of 1×105 cells per well. In order to determine the viral titer, six
10-fold serial dilutions of the virus containing medium was prepared, and NIH-3T3 cells
were infected by adding 1 mL of the diluted medium to the wells with the final polybrene
concentration of 4 μg/ml. The medium was replaced with selective medium containing
100 μg/ml of G418 (Life Technologies) 24 hours post-infection. The viral titer was
estimated by counting the number of colonies in the highest dilution that contained
colonies after one week of selection and by multiplying the number of colonies by the
dilution factor. For flow cytometry analysis of HA3.1 library expression in NIH-3T3 cells,
cells were stained with HC2 mouse mAb and anti-mouse-phycoerythrin (PE) 24 or 48
hours post-infection..
2.2.4 Stable selection of HA library expressing cells
Cells were infected and selected by the method used for viral titer determination.
Non-infected cells were used as a negative control and the cells were cultured in the
selective medium until there were no viable cells observed in the control population.
Expression levels before selection and after selection were analyzed by flow cytometry
after HC2 mouse mAb and anti-mouse-PE staining.
2.2.5 Analysis of pH-induced activation:
Adherent, non-confluent HA3.1 or wt HA and single point mutant expressing
HEK293 cells were detached using 0.05% trypsin-EDTA and cell suspension aliquots
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were transferred to 1.5mL microcentrifuge tubes and placed on ice. The HA expressing
cells were washed twice with PBS+0.1%BSA (8 g/L NaCl, 200 mg/L KCl, 1440 mg/L
Na2HPO4, 240 mg/L KH2PO4, and 1 g/L BSA) at 500xg using a benchtop
microcentrifuge. The cells were then pH-pulsed for 5 minutes at room temperature at
the appropriate pH. After the pH pulse HA3.1 were double-stained with mouse
monoclonal anti-FPV HA1 (HC2) and chicken anti-c-myc mAb. Wild-type HA or single
mutant HA expressing cells were labeled with either anti-FPV HA1 (HC2) or the trimer
and conformation specific mAb, HC58.66 Primary antibody incubations were done at
1:100 dilution on ice for 30-60 minutes. Following the primary incubation, the cells were
washed again with PBS+0.1% BSA and then labeled with a fluorescent secondary
antibody at a 1:100 dilution and incubated on ice 30-60min. Following the secondary
incubation, the cells were washed again in PBS and then analyzed by flow cytometry.
Only viable cells, as determined by propidium iodide (BD Biosciences) exclusion (10
μL/106 cells for 15 minutes at room temperature) and/or light scattering, were included
in the analysis by flow cytometry, and at least 10,000 gated events were analyzed for all
flow cytometric experiments.
2.2.6 Determination of Transition pH
Viable cell populations were determined by light scattering and gated for
analysis. The median fluorescence intensity (MFI) of the gated population was
determined using FlowJo flow cytometry analysis software (Ashland, OR). Plots of MFI
versus pH were created using the statistical software package Prism (Graphpad, La
Jolla, CA) and a dose-response curve was fitted using the following equation:

Y
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1

EC 50
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Where Y is the median fluorescence at a given pH, X is the pH, „Bottom‟ is the lower
plateau of the dose response curve, „Top‟ is the upper plateau of the curve and EC50 is
the pH at which HA is assumed to have transitioned to an irreversible conformation. An
EC50 value was extracted from the dose-response curve fit and considered to be the
“transition pH” at which HA refolds from a closed to an open conformation. Reported
transition pH values are averages from independent experiments.
2.3 Results
2.3.1 Previously identified HA mutants with altered activation pH
Linking phenotypic changes to genetic changes creates the ability to probe the
structure-function landscape and identify residues, or areas of the protein structure, that
are involved in the conformational refolding of fowl-plague virus hemagglutinin (FPV
HA). Previously, research in our lab developed a flow cytometry assay where HA
refolding is decoupled from membrane fusion and can conveniently be quantified by
immunofluorescent staining and flow cytometry (Figure 2.4).58 The development of this
flow cytometry assay for HA refolding allowed for the construction of three separate
libraries by error-prone PCR and the ability to use fluorescence-activated cell sorting
(FACS) to isolate HAs whose neutral pH conformations were either stabilized or
destabilized with respect to wild-type hemagglutinin (Figure 2.5). Mutants from each of
the three libraries were isolated and their genes sequenced to identify mutations that
may or may not be responsible for pH sensing (Table 2.1). This chapter will analyze
these previously identified mutations to try and identify individual mutations responsible
for pH sensing and how these mutations likely affect the structure-function relationship
of hemagglutinin.
In the previously developed assay, a set of monoclonal antibodies is used to
assess HA refolding where two antibodies, HC58 and anti-c-myc (9e10) (when HA2
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Figure 2.3 HA refolding decoupled from membrane fusion. A) HA expressing HEK293
cell monolayers are detached from culture plates using 0.05% Trypsin-EDTA. Cells are
then transferred to 1.5 mL microcentrifuge tubes for washing and immunofluorescent
labeling steps. B) Schematic of surfaced expressed HA refolding and
immunofluorescent staining flowing 5 minute pH pulse. At neutral pH (left), HA is in its
metastable neutral conformation with HC2 and HC58 epitopes available for antibody
binding (upper right) while the c-myc epitope is not. Following the pH pulse and
irreversible conformational change, HC2 and c-myc epitopes are available for
immunofluorescent staining while HC58 is not (bottom left). C) Crystral structure of H7
HA showing locations of HC2, HC58 and c-myc eptiopes. D) Following
immunofluorescent staining, cells are sorted (library) or analyzed (characterization) for
refolding with a flow cytometer. For all HA depictions (B and C), only monomers are
shown for clarity.
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Figure 2.4 pH pulse experiment for HA refolding. HA-expressing cells (red, upper left)
are subjected to a 5-minute pulse of pH buffer (pH 4.6 to 6.4 in increments of 0.2 pH
units). Following the 5 minute pulse, cells are quenched with pH 7.4 buffer to stop any
additional refolding. Cells are then labeled with a conformation specific mouse antibody
(HC58, specific for the neutral pH conformation) for 45-60 minutes at 4°C. The labeled
cells are then washed once and labeled with an anti-mouse second antibody for 45-60
minutes at 4°C. Cells are washed a final time and then analyzed by flow.
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Figure 2.5

Previous directed evolution of HA. A) Design of three separate libraries to

alter the conformational stability of HA. The top two library depictions illustrate that
libraries were sorted following a higher pH pulse step to activate only destabilized HA.
The bottom library design was more complicated. The library was initially pulsed at pH
5.2 to activate wild-type and destabilized HA. Thermolysin was then used to cleave the
fusion peptide, eliminating the c-myc epitope signal. The library was then re-pulsed with
pH 4.8 buffer to activate stabilized HA. B) Top panel represents the pH 5.6 library and
the bottom panel represents the pH 6.0 library before and after 3 rounds of sorting. C)
pH 4.8 library population following pH 5.2 pulse (right), thermolysin cleavage (middle),
and pH 4.8 pulse (left). Data in parts B and C reprinted from Lee, Jeong H.
“Engineering and Characterization of Influenza Hemagglutinin Properties in Mammalian
System”, PhD Dissertation, 2007.67
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11-20 is replaced with the c-myc epitope) (Figure 2.3C), only detect the neutral and low
pH conformations, respectively, while HC2 binds irrespective of HA conformation.66 HAexpressing cells are first trypsinized from the culture dish using 0.05% Trypsin-EDTA
and transferred to 1.5 mL microcentrifuge tubes for the washing and labeling steps. At
this point, cells are kept as close to 4°C as possible. HA-expressing cells are washed
twice with PBS+0.1% BSA. Following the second wash step, a 5 minute pH pulse is
applied to induce HA refolding. Citrate buffers with different pHs ranging from 4.6 to 6.4
in increments of 0.2 units were used to subject the HA-expressing cells to a 5 minute pH
pulse to induce HA refolding. Following the 5 minute pH pulse, cells were quenched
with pH 7.4 PBS. After the pH pulse and quenching with pH 7.4 buffer, the cells were
labeled with a conformation specific antibody. In the previously performed library
selections, anti-c-myc (9e10) was used to identify exposure of the fusion peptide upon
HA refolding. In this work, the conformation specific antibody, HC58, specific for the
neutral HA conformation was used. Cells were incubated with primary antibodies for
45-60 minutes, then washed once and labeled with a fluorescent secondary antibody.
Both 9e10 and HC58 are mouse monoclonal antibodies, so a anti-mouse secondary
antibody was used to detect binding of the primary antibody to HA. Again, cells were
incubated with the secondary antibodies 45-60 minutes on ice and then washed once to
remove any unbound antibody. The immunofluorescently labeled cells were then run on
a flow cytometer to analyze for HA refolding.
A number of studies using various biochemical assays have demonstrated that
wild-type hemagglutinins are typically fully refolded by pH 5.2 and transition from a
neutral conformation to the extended, low pH conformation around pH 5.4-5.5. Previous
work was performed to try and isolate HAs that were destabilized compared to wt HA.
Two HA libraries, HA3.2 and HA3.3, were created and exposed to a five minute pH
pulse of either pH 5.6 or 6.0, respectively (Figure 2.5 A and B). A brief pulse at
elevated pH allowed for any library members with destabilized HA to refold prior to
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library members that may be expressing wt-like or stabilized HA. Three rounds of
fluorescence-activated cell sorting (FACS) were used to enrich a population of HA that
was destabilized with respect to wild-type HA. Following the third round of sorting, the
two destabilizing libraries had been enriched to the point where 96% of HA3.2 and 88%
of HA3.3 had been activated by their target pH (Figure 2.5 B). Mutants from these two
libraries were isolated and mutations were identified by sequencing.
While there are numerous studies where investigators have either created, or
found, destabilizing hemagglutinin mutations there are very few reports of mutations
that stabilize HA in the presence of low pH.46 Even though Thoennes et. al. report on a
few mutations that appear to be stabilizing (H171Y and K512A), the authors were not
explicitly looking for stabilizing mutations but rather exploring the effect of ionizable
residues around the fusion peptide to trigger HA refolding.46 To identify mutations that
had a stabilizing effect, the HA3.4 library was first pulsed at pH 5.2 to activate all
destabilized and wild-type-like mutants. Refolded proteins with an exposed fusion
peptide with the c-myc epitope were then susceptible to proteolytic cleavage by
thermolysin,58; 68 making their conformational change undetectable. Following the
thermolysin digest with another pH pulse at pH 4.8 allows any stabilized mutants to be
activated and expose their fusion peptide along with the c-myc epitope for fluorescent
staining (Figure 2.5 A and C). Flow cytometry shows that after the first pulse at pH 5.2,
a significant population is positive for c-myc; however, following cleavage with
thermolysin, the population seen in the left panel of is no longer present in the middle
panel. Finally, reapplying another pulse with pH 4.8 buffer activates another significant
population presumably expressing stabilized HA. Library clones were isolated after two
rounds of sorting and mutations contributing to a stabilized HA conformation were
identified. This chapter will focus on the identifying mutations that are responsible for
the altered phenotypes selected for in the previous directed evolution experiments that
have just been described.
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2.3.2 Identification of Destabilizing Mutations
To further understand which mutation(s) were responsible for destabilization of
the hemagglutinin trimer, and to better understand what mechanism(s) drives HA
refolding, individual mutations were analyzed. Five representative clones from the
HA3.2 library and three clones from the HA3.3 library were previously isolated and
sequenced following the three rounds of sorting to identify a set of mutations that may
have contributed to the destabilization of the protein. From the sequenced clones of the
mature HA3.2 library, a total of ten unique mutations were identified out of fourteen total
mutations (Table 2.1). The three sequenced clones from the HA 3.3 library produced 3
unique mutations out of 7 total mutations. Interestingly, while both the HA3.2 and
HA3.3 library were designed to identify destabilized HA, the two distinct libraries only
shared one common mutation D166G.
The panel of mutations was thoroughly analyzed by creating hemagglutinin
trimers with individual mutations using site-directed mutagenesis. To capture the
behavior of wild-type HA, the c-myc epitope in the fusion peptide was not used to
assess HA refolding, but rather the conformationally specific antibody, HC58. HC58
binds to HA in its neutral-pH conformation at interfaces between HA1 headgroups of
two monomers; therefore as the headgroups dissociate upon HA refolding HC58
binding is abolished.66 Flow cytometry was used to measure the median fluorescent
intensity of the HC58 binding to HEK293 expressing cells following pH pulses in a range
of pH around the expected pH of activation. The median fluorescent intensity (MFI) was
plotted against pH and a dose-response curve was fitted to the plots (Figure 2.6). An
EC50 value was extracted from the plots and used as the transition/activation pH for
that mutant protein.
From the flow cytometry results two mutations each from the 5.6 and 6.0 pH
libraries appear to destabilize HA. I96M and W243S, originating from the HA 3.2 library
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Table 2.1 List of hemagglutinin mutants previously isolated by directed evolution for altered conformational
stability
Clones Activation
pH

Mutations

HA3.4.1

4.8

D93S

E462Q

HA3.4.2

4.8

HA3.2.1

5.6

HA3.2.2

5.6

HA3.2.3

5.6

HA3.2.5

5.6

HA3.3.1

6.0

D166G

HA3.3.2

6.0

D166G

HA3.3.3

6.0

Y155F

A168V

D240Y D247N
W243S

D166G
G142D

D166G

I96M

W243S

L407A

W243S

L407A S429P

Y218H
V188G

G365C
G237R

G365C

G237R

G365C
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Figure 2.6 HA normalized pH transition curves. HEK293 cells expressing HA point
mutations were exposed to buffered solutions at a range of pH spanning the expected
transition pH. Viable expressing cells, gated on light scattering, were analyzed for
refolding by flow cytometry using conformation specific antibody, HC58, and median
fluorescence was plotted against pH. Shown here are representative pH transition
curves for mutant D247N (blue), wt HA (black) and G365C. EC50 values, referred to in
this dissertation as the „transition pH‟, were extracted from these curves using Prism
software package.
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(pH 5.6 selection pressure), appear to be slightly destabilizing (Table 2.2). Meanwhile,
two mutations from the HA 3.3 library, G237R and G365C, are significantly destabilizing
(Table 2.2). Two of the three clones isolated from the HA3.3 library contained both
G237R and G365C mutations, while the third clone from the HA3.3 contained D166G
and G365C mutations with the D166G mutation not contributing to the high pH
activating phenotype. Meaning G365C is likely solely responsible for the destabilized
protein. The double mutation of G237R and G365C likely made HA highly destabilized.
2.3.3 Identification of Stabilizing Mutations
After analyzing individual mutations from the HA3.4 library clones the
stabilization of HA in response to lower pH appears to be due to a single mutation,
D247N. Interestingly, a second stabilizing mutation was also found in the HA3.2 library
which was screened after a pH pulse of 5.6. D247N has an activation pH midpoint of
4.8 about 0.6 less than wild-type hemagglutinin (Table 2.2). The S429P mutant was
further stabilized by about 0.4 pH units compared to wild-type HA making this mutation
moderately stabilizing. These mutations will be further discussed below.
2.4 Discussion
Here we report the use of directed evolution to identify novel mutations in fowl
plague hemagglutinin that contribute to either a stabilized or destabilized neutral pH
structure. Previous work to better understand HA refolding has relied mainly on two
approaches, selection of virus variants and rationally designed point mutants 35; 46; 47; 60;
64; 65; 69; 70; 71; 72

. While these approaches have proven successful in their ability to isolate

HA variants that are either acid-stable or undergo the irreversible conformational
change at elevated pH, they are intrinsically limited by the constraints of nature. HA
mutants isolated in amantadine resistance experiments, where amatadine hydrochloride
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Table 2.2 Transition pH for individual mutants
Mutation

Selection pH

Transition pH (EC50)

wild-type

-

5.545 ± 0.08

D93S

4.8

5.51 ± 0.04

Y155F

4.8

5.54 ± 0.05

A168V

4.8

5.56 ± 0.16

D240Y

4.8

5.35 ± 0.05

D247N

4.8

4.83 ± 0.18

E462Q

4.8

5.65 ± 0.08

I96M

5.6

5.79 ± 0.001

G142D

5.6

5.51 ± 0.05

D166G

5.6/6.0

5.50 ± 0.09

V188G

5.6

5.43 ± 0.22

Y218H

5.6

5.49 ± 0.10

W243S

5.6

5.67 ± 0.15

L407A

5.6

5.61 ± 0.02

S429P

5.6

5.06 ± 0.07

G237R

6.0

6.30 ± 0.16

G365C

6.0

6.09 ± 0.17

Note: Highlighted rows represent mutations that have a transition pH that is significantly
different than wild-type hemagglutinin. Green represents stabilizing mutations, orange
represents destabilizing mutations, and red significantly destabilizing mutations.
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affects the intracellular pH,65; 66 have been chosen based on the ability of cells treated
with amantadine to produce viral particles capable of lysing cells.64; 65 These mutants
are therefore somewhat limited in the sequence space they can sample because of the
necessity to retain membrane fusion activity and viral infectivity. Studies employing
site-directed mutagenesis often changed residues based on: locations previously
identified as affecting pH-sensing65, sequence alignment46; 60; 71, structurally interesting
locations such as the fusion peptide or fusion peptide pocket35; 72, or a combination of
these.47 Either way, previous studies have been limited because of selections based on
membrane fusion or sequence alignments where highly conserved amino acids are
typically not changed.
Directed evolution uses repeated rounds of selection to quickly enrich rare
populations and has been used to successfully engineer a variety of proteins with
improved fitness from single-chain antibodies73 to enzymes that can be used as
biocatalysts.74 Using error-prone PCR to introduce mutations into the gene for FPV HA
removed the natural constraint of fusion competency allowing for residues that are
normally highly conserved across all HA subtypes to be mutated. Out of the sixteen
unique mutations found in previous directed evolution screens, two of the mutations
(G365C and W243S) were found at residues that are conserved across all HA subtype
consensus sequences.75; 76 To our knowledge, of the 16 mutations found screening the
library of mutated H7 HAs, 15 have never been identified as mutations affecting pH
sensing and the sixteenth mutation, G365C, was found to be stabilizing in a previous
study.71
As previously mentioned, four mutations (I96M, G237R, W243S, and G365C)
were found that destabilized the neutral conformation of HA. Two of the mutations are
located at residues that are conserved among all HAs (W243 and G365) and three of
the four mutations are located in the HA1 headgroup (Figure 2.7). The majority of
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A)
G237R

W243S

D247N

I96M
S429P
B)
D247N

W243S
G365C
I96M

S429P

G237R

Figure 2.7 Structural locations of pH sensing mutations. A) Side image of
hemagglutinin trimer with mutations that affect pH-sensing shown as spheres and colorcoded according to Table 2.2. Coordinates used in the analysis are from PDB file
1HGF77 and the images were generated using PyMol software (http://www.pymol.org).
B) Top-down image of the HA trimer with same pH-sensing mutations displayed and
clustering toward trimer interfaces.
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previously identified pH-sensing mutations have been located in the HA2 subunit with
very few mutations found to sense pH in the HA1 headgroup.35; 46; 47; 64; 65; 70 The I96M
mutation allows HA to undergo its acid-induced refolding ~0.3 units higher than wildtype FPV HA most likely due to disrupting the side chain packing. In the neutral pH
conformation, the smaller side of isoleucine packs tightly into a small pocket created by
three loops of HA1: T64 to D66, D93 to E97, and M274 to V282 (Figure 2.8). The
additional length of the methionine side chain may have trouble fitting into this small
pocket and that likely destabilizes the surrounding contacts. One contact that is likely
altered as a result of Ile-Met substitution is the hydrogen bonding between Q277 and
E411. E411 has been previously identified as a residue that makes critical contacts
between the B-loop of HA2 and surrounding residues in the prefusion conformation and
that B-loop rearrangement is a critical step in the loop-to-helix transition that occurs in
HA2.60 Taken together, it seems most plausible that steric hinderances caused by the
methionine side chain eventually lead to disruption of hydrogen bonds between E411
and Q277, which allows for the neutral pH structure to become destabilized more
readily.
While the structural implications of I96M are somewhat ambiguous, the effects of
a Gly-to-Arg mutation at HA1 237 seem more straightforward. G237R raised the pH at
which HA undergoes its structural transition by 0.8 units, similar to that for G365C. Glu237 is located near the HA1-HA1 interface and is next to Arg-238. Introducing a second
arginine residue close to the HA1-HA1 interface likely contributes to long-range
electrostatic interactions that destabilize the interface. Two positively charged arginines
next to each other and located near positively charged residues on the apposing HA1
headgroup (K217 and H219) could provide a strong electrostatic repulsive force to
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B-loop of HA2

Gln-277

Glu-411

Figure 2.8 I96M mutation structural implications. Ile-96 is shown as ball-and-stick in
dark blue and the Ile-96-Met mutation is shown as ball-and-stick also, and colored
orange with the sulfur of the side chain yellow. The I96M mutation was modeled using
Swiss pdbViewer and the rotamer with the best score was chosen. Possible interactions
with the loop (colored lime green) containing Gln-277 may disrupt its interaction with
Glu-411 of the HA2 B-loop ultimately destabilizing the neutral pH structure.
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further destabilize the neutral pH conformation (Figure 2.9). The pKa of histidine is 6.0
and Mittal et. al. report that the pKa for each hemagglutinin monomer is between 5.6
and 5.7 indicating that histidine residues could play an important role in pH sensing. 78
Thus, while it is impossible to precisely know the pKa of H219, it likely becomes
protonated providing additional positive charge at the same interface of the G237R
mutation. The additional charge provided by the mutation, as well as the positive
charge associated with the protonation of His-219 as the pH drops, disrupts the HA1
interface sufficiently enough for the headgroups to dissociate and HA2 to refold into the
extended coiled coil, low pH conformation.
Arguably, a more interesting mutation to be identified as being responsible for the
destabilization of the neutral pH conformation is W243S. W243S elevated the transition
pH of HA by ~0.2 but W243 is a conserved residue among all HA subtypes and is
located at an interface between HA1 and HA2 of an adjacent monomer. W243 fits into
a hydrophobic pocket created mainly by the HA1 headgroup and Val415 of the B-loop of
the neighboring HA2. As previously mentioned, the B-loop of HA2, which under goes
the loop-to-helix transition upon activation, has been proposed to transition to a relaxed
state under acidic conditions prior to undergoing its irreversible conformational
change.79 When W243 is occupying the hydrophobic pocket in the metastable
structure, Val415 is unable to occupy the hydrophobic pocket of W243 thus maintaining
the prefusion conformation (Figure 2.10). However when serine is introduced in place
of W243, the hydrophobic pocket is unoccupied and valine is able to position its side
chain in the hydrophobic pocket allowing the B-loop to adopt its “relaxed” form prior to
the loop-to-helix transition. The proposed ability of valine to occupy the hydrophobic
pocket would allow HA2 to more readily undergo its acid-induced conformational
change thus elevating the transition pH of the protein.
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Figure 2.9 G237R electrostatic interactions. The G237R mutation was modeled using
Swiss pdbViewer and shown as green spheres. R238 (purple) of the same monomer,
as well as the locations of K217 and H219 (gray) of FPV HA, are also shown as
spheres. The proximity of these positively charged residues likely contributes to
electrostatic repulsion of the HA1 headgroups destabilizing the protein.
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Figure 2.10 Effect of W243S mutation on HA structure and pH sensing. A) Structural
rendering of W243 occupying a hydrophobic pocket in the neutral HA0 structure (PDB
1HA0).80 Val-415 does not readily occupy the hydrophobic pocket at neutral pH when
W243 is present. B) The mutation W243S clears way for Val-415 to move into the
hyrodrophobic pocket thus allowing the B-loop of HA2 to swing outward into a “relaxed”
conformation, primed to undergo the loop-to-helix transition that is essential in the
spring-loaded refolding model. The two HA2 structures shown are at pH 8.1 (orange,
PDB 3QQB) where the B-loop is still closely packed with the α helix, and at pH 5.3
(cyan, PDB 3QQO). The pH 5.3 structure was stabilized in the closed conformation by
H2-HA2R106H and shows the B-loop adopting a “relaxed” position assumed to be an
intermediate structure before undergoing the loop-to-helix transformation.60
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A)

B)

Figure 2.10 Continued
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Results in this study show that the one of most destabilizing mutations found
G365C, and together with D247N, had the largest deviation in transition pH from
type HA (~0.6-0.7). Gly-365 is located at the end of the fusion peptide in the
proximal region of HA2 near where HA1 and HA2 are covalently attached via a
bond between C14 and C479. Substitution of Gly-365-Cys places an additional
cysteine less than 12Å away from the HA1-HA2 disulfide (
Figure 2.11). We propose that G365C interferes with the native disulfide in at
least one HA monomer, causing a gross displacement of that HA1 head group leading
to a loss, or disruption, of all stabilizing contacts in the trimer head group. Previous
work examining disulfide bond formation in HA found that mutant HAs with a C14S or
C479S mutation failed to form disulfide bonds with any of the native cysteine residues of
HA1, but confirmed that a small portion of mutants were transported to the cell surface
in a non-native conformation.81 The formation of a new disulfide bond between C14 and
G365C would likely only occur in a few monomers given the propensity of HA to form
native disulfide bonds. Formation of new disulfides in only one or two monomers would
destabilize the entire trimer while still allowing the refolding of the other monomer(s) and
exposure of the c-myc epitope that was used in the directed evolution work to identify
destabilized HA, from which the G365C mutation was isolated. Interestingly, our flow
cytometric data is in direct conflict with a previous study that made the same mutation in
another H7 variant, A/Netherlands/219/03 (H7N7).71 The study by Ilyusina et. al., found
that substituting Cys for Gly232 resulted in a stabilized HA that refolded 1.0 point below
the pH of the wild-type A/Netherlands/219/03 HA. While the different HA variants may
explain some of the differences between the previously reported results and ours, it is
likely not enough to explain a ~1.7 pH difference in transition pHs between two closely
related HAs.
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Directed evolution was also used to identify mutations that stabilized
hemagglutinin and lowered the pH at which the protein undergoes its irreversible

40

Figure 2.11 G365C mutation and disulfide bonding. G365C is shown as magenta
spheres near the native disulfide that covalently links the HA1 and HA2 subunits. The
destabilizing affect arising from the G365C mutation may be due to disulfide bond
formation between the new cysteine of HA2 and Cys-14 which is one-half of the native
disulfide. A new disulfide would likely shift the entire HA1 headgroup therefore
destabilizing the entire protein.
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conformational change. Two mutations have been identified as stabilizing the neutral
conformation, D247N and S429P. However, only D247N was found via screening of the
4.8 pH-pulsed library. S429P was identified in clone HA3.2.5 along with two
destabilizing mutations I96M and W243S, supporting the idea that multiple mutations
with in HA can be cumulative.65 S429P was found to stabilize the trimeric structure by
0.4 units from the wild-type transition pH. S429P is located near the membrane distal
segment of the long α-helix of HA2. A serine to proline mutation likely stabilizes the
neutral pH conformation through interactions between the large α helix of HA2 and the
neighboring B-loop. In H2 HA, Phe-405 of the B-loop packs tightly against Phe-430 of a
neighboring HA2 stabilizing the neutral pH structure.60 In H7 HA, and specifically for
Rostock/FPV HA, there is no aromatic side chain at position 430 or adjacent residues in
a neighboring HA2 to make an aromatic stack with the conserved Phe-405 to stabilize
the structure. The aliphatic ring structure of a proline substitution provides additional
hydrophobic contacts with Phe-405 compared to serine providing a stabilizing force to
keep the HA in an acid-stable conformation(Figure 2.12).82 D247N stabilized the
transition pH of HA by 0.6 and is located in the HA1 headgroup at the HA1-HA1
interface. The side chain of Asp-247 is positioned directly across from Glu-414 of an
adjacent HA2 subunit, creating a charge repulsion that destabilizes the neutral
conformation to some extent and is a critical component of the metastable conformation
(Figure 2.13). Substitution of a neutral asparagine residue is not only a conservative
mutation, but it acts to eliminate the charge repulsion between D247 and E414‟
stabilizing the neutral conformation of HA.
Interestingly, all of the destabilizing mutations were found in multiple clones
except for I96M and each of the stabilizing mutations only appeared in one clone. Of
the six mutations identified in this study, all but G365C and S429P were located in the
HA1 headgroup. The locations of the mutations found through this directed evolution
study reinforces the model of the HA1 headgroups acting as a “clamp” preventing
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Phe-405

S429P

Figure 2.12 Stabilization of B-loop by S429P mutation. The addition of a aliphatic ring
by the mutation of Ser-429 to proline allows the aromatic residue of Phe-405 of the Bloop to be stabilized in a ring packing manner. The S429P mutation was modeled in
using Swiss pdbViewer and the lower scoring trans oriented side chain was chosen.
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Figure 2.13 Asp-247-Asn mutation relieves electrostatic repulsion. In the native HA
structure the negatively charged side chain of Asp-247 is directly opposed by the
negatively charged side chain of Glu-414 and separated by roughly 4Å. The proximity
of both negative charges would destabilize the HA1-HA1 interface priming it for
refolding. By substitution of Asp with Asn, that charge repulsion is relieved stabilizing
the interface.
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refolding of hemagglutinin. Other studies have proposed that the B-loop of HA2 and
regions of HA1 that interact with this loop are critical for controlling the pH of fusion.35; 60
Our results tend to agree with this finding based on the number of mutations that likely
interact with the B-loop of HA2 in some capacity. We propose, more specifically, that it
is the HA1 headgroup that acts as the primary pH-sensing mechanism and HA1-HA1
interactions must be sufficiently interrupted by the increasing concentration of protons
within the endosome, so that HA1 headgroups dissociate allowing the HA2 subunit to
undergo its conformation rearrangement. The total displacement of HA1 globular
domains is in agreement with a previous computational study that showed complete
dissociation of the head groups is the most energetically favorable pathway to the low
pH, irreversible conformation.63 Through directed evolution, mutations were made to a
few highly conserved residues that had previously not been explored for pH-sensing
and the location of both stabilizing and destabilizing mutations within the HA1
headgroup provide clues to HA1 acting as the primary pH sensor that controls
hemagglutinin switching.
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Chapter 3 : Engineering and characterization of an improved chimeric
adhesive switch via directed evolution using yeast surface display
3.1 Introduction
Nature has evolved to include many complex processes that require
sophisticated proteins capable of controlling cellular signals and functions. This is often
accomplished through allosteric regulation where output signals are modulated in an
„on/off‟ fashion by the presence or absence of effector molecules (e.g., small molecules
or ligands). Allosteric regulation was first proposed fifty years ago as a way to describe
proteins in metabolic networks that regulated the production of metabolites and revolved
around two core concepts which haven‟t changed; first, the effector binding site is
spatially distinct from the active site, and, second, the effect is entirely due to
conformational changes within the protein structure.10
These key concepts have been the basis for a number of different approaches to
engineering functional molecules for use in sensing, diagnostic or therapeutic functions.
Controlling transgene networks for the treatment of diseases is reliant upon precise
control of genes at the transcription and translation levels with small molecules, such as
siRNA, or gene switches.83; 84 One such example of a gene switch is nuclear hormone
receptor, hERα, which had its ligand selectivity engineered from its natural ligand 17βestradiol to a synthetic ligand 4,4‟-dihydroxybenzil (DHB) using site saturation
mutagenesis and directed evolution.
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Protein switches have also been created for

diagnostic and sensing applications by fusing heterologous genes together to couple
two disparate protein functions in a modular fashion. Examples of modular switches
created by varying degrees of domain insertion include fusions of TEM1 β-lacatamase
(BLA) and maltose binding protein (MBP), photoprotein (AEQ) and sulfate-binding
protein (SBP), and between the photoactive LOV2 domain of Avena sativa and E. coli
trp repressor.86; 87; 88 Until recently, proteins such as GFP, luciferase, dihydrofolate
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reductase (DHFR) and β-galactosidase have been heavily relied upon in engineering
protein switches as they provide simple phenotypic screening and selection
strategies.14; 15
Recent work in our lab has demonstrated the ability to modulate cellular
adhesion between the αL inserted (I) domain and an intercellular adhesion molecule-1
(ICAM-1)-coated surface under shear flow by the presence or absence of an effector
peptide.89 The allosteric rearrangement within the I domain was exploited to make a
functional switch by fusing the EF3 and EF4 hands of calmodulin to the N- and Ctermini of the I domain, respectively (Figure 3.1 D).
3.1.1 I domain
In an innate immune response, inflammation is a front-line defense against
infection, injury or trauma. Inflammatory responses typically only last a few days and
include a wide array of cell types, receptors, selectins, and chemokines. While
inflammation tends to be a transitory response, prolonged inflammation is responsible
for a number of pathological and clinically relevant conditions such as rheumatoid
arthritis, Crohn‟s disease, and transplant rejection where prolonged inflammation leads
to tissue and organ damage. Among the many players of the inflammation cascade
arguably the most important are integrins.
The inflammatory cascade begins when blood vessels dilate and flow is
slowed.90 Inflammed endothelial cells express E- and P-selectin on their surface, which
in conjunction with reduced flow allows leukocytes expressing P-selectin glycoprotein
ligand 1 (PSGL1) to transiently tether to the vasculature. The transient interactions
between endothelial cells and leukocytes are mediated by the high on- and off-rates of
the selectin-ligand interactions; this selectin-mediated rolling allows for intracellular
signaling to occur within the leukocyte via chemokine binding to G-protein coupled
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Figure 3.1 Role of αL I domain in LFA-1 and a fusion protein switch. A, B and C)
Activation of LFA-1 from a bent, closed, low-affinity conformation (A), to an extended,
closed, low-affinity conformation (B, left). An inside-out signal is transduced up the βleg resulting in alteration of the β I-like domain (blue domain) MIDAS allowing Glu-310
to bind and pull down the α7 helix of the I domain (pink domain, B right). In nature, the
bond between ICAM-1 and the αL I domain is strengthened by force (C). D) The
pulling down of the α7 helix is mimicked in our switch construct by the binding of the
EF3 and EF4 hands of calmodulin to a peptide of smooth muscle myosin light chain
kinase (smMLCK, purple helix). The original chimeric fusion between I domain and the
EF3 and EF4 hands of calmodulin, prior to any mutagenesis or directed evolution, is
referred to in this dissertation as “wild-type switch.” Upon binding, the α7 helix (orange)
is displaced downward allowing for the adoption of a high affinity conformation by the I
domain. Mg2+ is depicted as a red sphere at the top of the MIDAS.
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Figure 3.1 Continued
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receptors (GPCRs).91 Activation of GPCRs by chemokines induces a complex signaling
network, which at this time is not completely understood, 91 but that activates integrins
by actin-binding proteins such as talin-1, kindlin, or filamin.11; 91 Binding of integrin
cytoplasmic domains by actin-binding proteins separates the α and β cytoplasmic
domain tails inducing a „switchblade-like‟ conformational rearrangement into an
extended, primed conformtation in a process termed „inside-out signaling‟ (Figure 3.1C).
11; 90; 92

Integrin avidity, the total adhesiveness of the ligand-protein interaction, is

composed of integrin affinity for its ligand and the valency (number of contacts) between
the protein and ligand. Once activated, integrins facilitate leukocyte firm adhesion to the
endothelium followed by crawling and then paracellular and transcellular transmigration
into the site of inflammation to carry out its immunological activity.

91

Lymphocyte function-associated antigen-1 (LFA-1) is probably the most widely
studied and and well characterized member of the integrin family. It is a heterodimeric
transmembrane protein composed of noncovalently associated α and β subunits. While
each subunit is large and complex, the ligand binding site is contained solely within the
180 amino acid inserted (I) domain of the αL subunit of LFA-1 (αLβ2, CD11a/CD18) 93.
The crystal structure of the αL I domain reveals a central hydrophobic pocket composed
of six β-strands adopting a Rossman fold surrounded by 7 amphipathic α helices. 9; 93; 94
A Mg2+ ion is located at the “top” of the crystal structure as part of a metal iondependent adhesion site (MIDAS), and is ligated by five residues, D137, S139, S141,
T206 and D239 (Figure 3.2).93 LFA-1 binds intercellular adhesion molecules (ICAMs),
of which it has the highest affinity for ICAM-1.11; 93 ICAM-1 binds to the I domain of
LFA-1 through coordination of an acidic residue (Glu34) to the MIDAS of I domain,
which is surrounded by a ring of hydrophobic residues in both the ICAM-1 and I domain.
A salt bridge between Glu-241 and Lys-39 of I domain and ICAM-1, respectively, is also
crucial for ligand binding.93 The exposure of the MIDAS is in conjunction with the axial
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Figure 3.2 αL I domain. A) Low-affinity, “closed”, conformation of αL I domain. The
magnesium ion of the MIDAS (metal ion-dependent adhesion site), in the top portion of
the structure, is colored in yellow. Residues coordinating the Mg2+ of the MIDAS are
shown as ball and sticks, where oxygen atoms are red and nitrogen atoms are blue.
Glu-310 acts as a pseudo-ligand for the β2 I-like domain and ligates the Mg2+ of the Ilike MIDAS in a similar fashion to Glu-34 of ICAM-1 to the MIDAS of the αL I domain.
B) High affinity, “open”, conformation I domain structure. Again, the Mg2+ of the MIDAS
is shown as a yellow sphere. The α7 helix has been displaced downward by 10Å
compared to the low affinity conformation. Additionally, the coordinating residues have
also rotated as a result of the allosteric rearrangements due to the motion of the α7 helix
and are now in a position to facilitate ICAM-1 binding. C) ICAM-1 bound to the I
domain showing ligation between Glu-34 of ICAM-1 and the Mg2+ of the I domain
MIDAS.

51

Figure 3.2 Continued
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downward movement of the α7 helix of I domain by about 10 Å. The downward
movement of the α7 helix of the I domain acts as a pulley causing a rearrangement of
the metal ion-dependent adhesion site (MIDAS) drastically altering the affinity for the
ligand, ICAM-1.9; 11; 92; 95 This downward movement toward the β I-like domain also
allows for interaction between Glu-310 of the linker between the α I domain and β
propeller domain and the β I-like MIDAS. This conformational interaction between the
different subunits allows LFA-1 to transduce signals bidirectionally through the different
domains.9; 92; 93; 94; 96 This allosteric interaction between the I domain and the I-like
domain in the β subunit makes the I domain an ideal candidate for engineering a novel
molecular switch.
The allostery of the I domain can be coupled with other protein domains to create
a chimeric protein switch. Additionally, the flexibility seen within I domain with the
proximity of its N- and C-termini makes I domain very suitable for circular permutation.
Circular permutation, coupled with allosteric proteins, gives engineers a powerful
combination to create novel molecular switches with increased affinities or functions

14;

86; 97

. Previous work has demonstrated that the individual EF-hands of each calmodulin

subdomain can solubly recombine in the presence of the target peptide, smooth muscle
myosin light chain kinase (smMLCK).98 Fusion of the EF-hands to the termini of the I
domain likely produces a disruption in the allosteric region of the I domain due to the
repositioning of the α7 helix upon binding of the EF3 and EF4 hands to smMLCK
peptide leading to a three-fold increase in adhesion (Error! Reference source not found.
D).89 Here we show that through focused mutagenesis on the allosteric region of the I
domain and directed evolution a near twenty-fold improvement in switch activity was
achieved. This improvement in switch activity has resulted in mutant switches that were
effectively “on/off” in their behavior.
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3.2 Materials and Methods
3.2.1 Yeast strains and plasmid
S. cerevisiae EBY100 (MATa AGA1::GAL1-AGA1::URA3 ura3-52 trp1 leu2Δ1
his3Δ200 pep4::HIS3 prb1_1.6R can1 GAL) cells were transformed with pCT302derived vectors allowing for selection under Trp- and Ura- conditions and surface
expression of proteins under the galactose inducible GAL1,10 promoter.99 pCT302 was
used as the expression vector for all experiments except for circular permutation and
fusion constructs were cloned in using NheI and BamHI restriction sites. Routine stickyend restriction enzyme digestion and ligation reactions were performed as follows.
Briefly, 10 μL of purified plasmid DNA was digested using 1 μL (20 Units) of NheI-HF
(NEB) and 1 μL (20 Units) of BamHI-HF(NEB), 4 μL of NEB CutSmart buffer (10X), 0.4
μL BSA (100X) and 23.6 μL of dH2O in a total reaction volume of 40 μL. The
preparative double digest was placed in a 37°C water bath for 2-3 hours. The reaction
was stopped with 10X stop buffer (50% (w/v) glycerol, 0.1 M EDTA (pH 7.5), 1% (w/v)
SDS, and 0.1% (w/v) bromophenol blue). Digested DNA was analyzed by gel
electrophoresis and the correctly sized bands were excised and purified using the
Promega Wizard gel purification kit following the manufacturer‟s instructions. Ligation
reactions contained 3 μL of purified linearized vector, 6 μL of purified DNA to be
inserted, 2 μL of T4 Ligase buffer, 8 μL of dH2O and 1 μL of T4 Ligase. Ligation
reactions were carried out at 16°C overnight and the following day, 2 μL of ligation
reaction was used to transform E. coli. Use of NheI and BamHI restriction sites allows
two epitope tags (HA and c-myc) on either side of the gene of interested to be
expressed in the ORF. For the circular permutation library, the AfeI restriction site was
inserted into pCT302 via PCR on the C-terminal side of NheI and the N-terminal side of
BamHI, respectively, allowing for blunt-end cloning and termed vector pCT-JVP (primer
sequences can be found in Appendix 6). Briefly, the PCR reaction to insert the AfeI
restricition sites used 5 units of Taq DNA polymerase (NEB) with 5 μL of 10X standard
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Taq buffer, 200 μM dNTPs, roughly 50 ng of plasmid DNA, and 0.15 μM of each primer.
PCR cycles used were as follows: initial denaturation at 95°C for 2 minutes, then 30
cyles of 95°C for 30 seconds, annealing at 62°C for 30 seconds, extension at 68°C for
50 seconds, followed by a 5 minute final extension at 68°C. The PCR product was
inserted into the TA-cloning vector, pCR2.1, using the TOPO TA cloning kit following the
manufacturer‟s instructions (Invitrogen). The gene fragment containing the newly
inserted AfeI restriction sites was then transferred from the cloning vector to a linearized
pCT302 vector using restriction enzyme digestion and ligation. The AfeI restriction sites
were confirmed by gel electrophoresis and sequencing. Yeast were grown in the semidefined media SD-CAA (20g/L dextrose, 6.7 g/L yeast nitrogen base without amino
acids, 5.4 g/L Na2HPO4, 9.7 g/L NaH2PO4·H2O, and 5 g/L CAA) at 30°C overnight. The
following day, expression was induced by subculturing at an OD600 of 1 and grown
overnight in SGR-CAA (same as SD-CAA expect 2% (w/v) dextrose is replaced with 2%
galactose and 2% D-Raffinose).
3.2.2 Magnetic-activated Cell Sorting (MACS)
Yeast were grown and induced as previously described. Following overnight
induction in SGR-CAA at 30°C, 3x106 cells (OD600 of 0.3) were transferred to
microcentrifuge tubes for washing and immunostaining. 108 yeast were washed twice
with 1 mL of PBS(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4)
supplemented with 1 mM MgCl2 and 0.1% BSA. A MACS LS column (Miltenyi Biotech,
Auburn, CA) was prepared by washing the column with 3 mL of PBS supplemented with
2 mM EDTA and 0.05% BSA. 60 μL of ICAM-Fc (R&D Systems, Minneapolis, MN) at
200 μg/mL was added to 200 μL of Protein G magnetic beads to saturate the beads
with ICAM; the ICAM-Protein G beads were incubated at 4°C for 45 minutes. The
ICAM-Protein G beads were applied to the LS column and washed three times with 5
mL of PBS with 1 mM MgCl2 and 0.1% BSA to remove an unbound ICAM-Fc. The
complexed ICAM-Protein G beads were eluted with 500 μL of buffer and 450 μL of the
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ICAM-Protein G beads were then applied to 108 yeast. The library and complexed
ICAM-Protein G beads were incubated for 1 hour at 4°C. Meanwhile, a new LS column
was prepared as previously described. The yeast/bead mixture was added to the
column, washed with buffer as before, and eluted with 5 mL of PBS plus 2 mM EDTA
and 0.05% BSA. The eluate was then used to inoculate 245 mL of SD-CAA.
3.2.3 Flow cytometry
Yeast were grown and induced as previously described in section 3.2.1.
Following overnight induction in SGR-CAA at 30°C, 3x106 cells (OD600 of 0.3) were
transferred to microcentrifuge tubes for washing and immunofluorescent labeling. Yeast
were washed twice with 500 μL Labeling Buffer (137 mM NaCl, 2.7 mM KCl, 10mM
Na2HPO4, 2mM KH2PO4, 10 mM MgCl2, and 1 mM CaCl2). Following the washes, cells
were incubated with mouse anti-c-myc antibody 9E10 (ascites fluid, Covance,
Princeton, New Jersey) at a 1:100 dilution in Labeling Buffer for 45 to 60 minutes at 4°C
along with either smMLCK peptide or a scrambled version of smMLCKp (henceforth
referred to as „scrampep‟) at a concentration of 10 μM. Yeast were washed once with
500 μL of Labeling Buffer then resuspended in 30 μL for labeling with fluorescent
secondary antibodies and precomplexed ICAM-Fc/anti-Fc AF647. 1.5 μL of ICAM-Fc
per sample (200 μg/mL) (R&D Systems, Minneapolis,MN) was precomplexed with Alexa
Fluor 647-conjugated goat anti-human anti-Fc secondary antibody (Jackson
ImmunoResearch, West Grove, PA) at a ratio of 1:1.6 at 4°C for at least 60 minutes.
Yeast were costained with precomplexed ICAM-Fc/AF647 anti-Fc, at a final ICAM-Fc
concentration of 10 μg/mL, goat anti-mouse Alexa Fluor 488 (Invitrogen) at 1:100 and
smMLCKp or scrampep at room temperature, protected from light for 1-2 hrs. Following
the secondary incubation, yeast were spun down at 10,000xg for 1 minute and
resuspended in 1 mL of fresh Labeling Buffer. Samples were analyzed on an Accuri C6
flow cytometer (BD Biosciences, Ann Arbor, MI). 10,000 events were collected per
sample and gated based on size. Background-corrected mean AF647 fluorescence
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(i.e., ICAM-1 binding) was normalized by background-corrected mean AF488
fluorescence (i.e., full length protein surface expression). Normalized mean
fluorescence of ICAM-binding of samples incubated with smMLCKp was divided by
normalized mean fluorescence of ICAM-binding of samples incubated with scrampep to
calculate a fold-change in ICAM binding. The following equations outline the foldchange calculations:

NMFI

MFI 647 sample

MFI 647bkgd

MFI 488sample

MFI 488bkgd

Fold Change

NMFI smMLCKp
NMFI scrampep

where NMFI is the normalized mean fluorescence intensity, MFI 647sample is the mean
fluorescence intensity due to ICAM-binding by the sample protein , MFI647bkgd is the
mean fluorescence intensity of ICAM binding by a negative control population
expressing a disparate protein on the yeast surface, MFI 488sample is the mean
fluorescence intensity of protein expression by the sample protein and MFI 488bkgd is
the mean fluorescence intensity of protein expression by uninduced yeast.
3.2.4 Library construction of circularly permutated I domain
A short, six amino acid linker containing two BamHI restriction sites used to
circularize the gene (GGGSG) was added by PCR and referred to as Id6L. 400 μg of
plasmid DNA containing Id6L was digested with 2,000 units of BamHI (New England
Biolabs Inc., Ipswich, MA) for six hours at 37°C. The digest was stopped with 10X stop
buffer (recipe). Linearized Id6L was gel purified and then ligated into circular genes
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using T4 Ligase (NEB) overnight at 16°C. Overnight ligations were desalted using
Promega PCR clean-up kit (Promega, Madison, WI). Circularized Id6L (10 μg) was
then digested with 20 mUnits of DNaseI (NEB) for 10 minutes at room temperature in a
total reaction volume of 300μL. The DNase digest was stopped with 6 μL of 0.5M
EDTA to a final concentration of 10 mM and heat inactivated at 65°C for 10 minutes.
Following heat inactivation, digested DNA was desalted as previously described. About
3.5μg of digested DNA was repaired using 12 U of T4 ligase, 3U T4 polymerase and
200μM dNTPs with 10X T4 ligase buffer in a total reaction volume of 200μL. The DNA
repair reaction was carried out at 12°C for 30 minutes and heat deactivated at 75°C for
20 minutes using a thermocycler. Each step is the circular permutation process was
verified by gel electrophoresis. pCT312 (~12 μg plasmid DNA) was digested with 15
units of AfeI for at least 2 hours and heat inactivated at 65°C for 20 minutes. Following
heat inactivation of the AfeI enzyme, digested vector was dephosphorylated using
Antarctic phosphatase at 37°C for 40 minutes and then heat inactivated at 65°C for 10
minutes. Digest, dephosphorylated pCT312 was analyzed by gel electrophoresis and
the linearized, dephosphorylated vector was gel purified for ligation with the circular
permuted Id6L library. Circularly permuted Id6L library was ligated with linearized,
dephosphorylated pCT312 at a ratio of 3:1 using T4 ligase and 5% PEG3350 with 10X
T4 ligase buffer in a total reaction volume of 120μL overnight at 16°C. Overnight library
ligations were transformed into MegaX DH10B electrocompetent cells (Life
Technologies, Carlsbad, CA) using 3 μL of ligated DNA and 20 μL cells per
transformation. Three transformations were pooled and recovered for 1 hour at 37°C
prior to plating serial dilutions and library size was estimated to be 1x106 the following
day. Library DNA was purified and frozen for future use. The circularly permuted library
was transformed into yeast using the lithium acetate method.100
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3.2.5 Construction of switch library
Random mutagenesis of the α7 helix and EF4 hand was performed using
nucleotide analogs. Ten cycles of error-prone PCR using 2.5 units of Taq polymerase
and 500μM each of dPTP and 8-oxo-dGTP (TriLink Biotechnologies, San Diego, CA)
introduced mutations into the switch gene between two ClaI restriction sites located
within the gene. Homologous recombination using 50-bp of homology on each side of
the ClaI restriction sites allowed for efficient recombination of the mutagenized gene.
Seven electroporations each containing 1 μg of vector DNA and 1.2 μg of library insert
per 50 μL of EBY100 were pooled together and transformed yeast were allowed to
recover in YPD (2% w/v dextrose, 2% w/v peptone, and 1% w/v yeast extract) for 1 hr at
30°C. The transformed yeast library was then spun down at 1,000xg for 3 minutes and
resuspended in 10mL of SD-CAA and serial dilutions were plated. Library size was
estimated to be 1.4x107.
3.2.6 Fluorescence-activated cell sorting
The library was sorted a total of four times using alternating rounds of positive
and negative selections to enrich for yeast that displayed improved switching behavior
in response to the presence of the smMLCK peptide. The first round of library sorting
was a positive selection to enrich for a population that bound ICAM-1 with high affinity in
the presence of 10 μM smMLCK peptide. The second and third rounds were negative
sorts to deplete the library of yeast that bound ICAM-1 in the presence of the scrambled
peptide at 10 μM. The fourth round of sorting was a positive sort to re-enrich for ICAM1 high affinity binders in the presence of 10 μM smMLCK peptide. Library expressing
yeast were grown and induced as previously described. Following overnight induction
at 30°C for at least 20 hours, 3.5x107 cells (OD600 = 3.5) were aliquoted and
immunostained as previously described. Briefly, cells were washed with Labeling Buffer
then labeled with anti-c-myc mouse monoclonal antibody, 9E10 (Developmental Studies
Hybridoma Bank, University of Iowa) at a dilution of 1:50 for 1 hour on ice. During the
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primary incubation, library expressing yeast were incubated with either 10 μM smMLCK
peptide or 100 μM scrambled smMLCK peptide. Following the primary incubation, cells
were washed with Labeling Buffer then labeled with precomplexed ICAM-1-Fc/anti-Fc
AlexaFluor 647, smMLCKp at 10 μM or scrampep at 100 μM, and goat anti-mouse
AlexaFluor 488 at a 1:100 dilution.
3.2.7 Protein purification
pET28b(+) (Novagen, Darmstadt, Germany) was used as the soluble protein
expression vector. Restriction sites, NheI and XhoI, were used to insert the gene of
interest into the ORF of pet28b(+) allowing for proteins to be expressed with a Nterminal His6 tag and a C-terminal c-myc tag to allow for diagnostic determination of full
length protein. E. coli BL21(DE3) were transformed by electroporation using 1 μL of
plasmid DNA per 50 μL of BL21(DE3) cells with plasmids containing genes encoding for
either high-affinity I domain mutant F265S or fusion, switch proteins. Overnight BL21
cultures were diluted 1:50 into fresh LB-Kan (50 μg/mL) media and induced with 1M
isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1mM at an
OD600 between 0.4 and 0.6. Cells were allowed to continue growing following induction
for another 3-6 hours. Cells were harvested by centrifugation at 5,000xg for 10 minutes
and frozen cell pellets were stored at -20°C until the protein was extracted. Cell pellets
were thawed on ice and then resuspended in 10 mL/g cells B-PER (Thermo Scientific,
Rockford, IL) and 5 μL/g cell pellet of DNaseI (NEB). Cell suspensions were
homogenized with a needle and syringe for about 5 minutes and allowed to incubate at
room temperature for 15 minutes with mild shaking. Soluble protein (fusion protein
switches) was collected in the soluble fraction following centrifugation at 15,000xg for 15
minutes. High affinity I domain is found in inclusion bodies and had to be further
purified from inclusion bodies. The pellet containing inclusion bodies was resuspended
in 5 mL B-PER and 4 μL Lysozyme (50 mg/mL) and homogenized, incubated at room
temperature and centrifuged as with the separation of the soluble fraction previously
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described. This process was repeated twice more to isolate inclusion bodies and then
resuspended in Buffer A (50 mM phosphate, 8 M urea, pH 7.5) and boiled for 1 hr.
Protein refolding was accomplished using an on-bead method.101 Briefly, solubilized
H.A. Id was added to prepared TALON cobalt resin (Clontech, Mountain View, CA) and
shaken overnight at 4°C. The slurry was then washed twice with 40 mL of refolding
buffer (50 mM phosphate, 1 mM MgSO4, 5% (v/v) glycerol, pH 7.5) and resuspended in
30 mL of refolding buffer and allowed to shake gently overnight at 4°C. The
beads/protein were collected in a column, washed twice with 5 CV of Equilibrium/Wash
Buffer (50 mM phosphate, 300 mM NaCl, pH 7.0) and eluted with 2X 1.5CV of Elution
Buffer (50 mM phosphate, 300 mM NaCl, 300 mM imidazole, pH 7.0). Fractions were
confirmed by western blotting or Coomassie staining. His-purified proteins were further
purified using the ÄKTApurifier with a Superdex 200 10/300 GL column (GE Healthcare
Bio-Sciences, Pittsburgh, PA) according to the manufacturer‟s instructions to remove
impurities that eluted from the TALON resin. Briefly, purified proteins were dialyzed into
SPR Buffer (20 mM Tris, 150 mM NaCl, 10 mM MgCl2, 2 mM CaCl2, 0.01% (v/v)
Tween-20, pH 8.0) using Slide-A-Lyzer cassettes (Thermo) following the manufacturer‟s
instructions. Briefly, 3 mL of eluted protein was added to the cassette, dialyzed in
2X500 mL of SPR buffer at room temperature for 2 h each. Buffer was then replaced
with 500 mL of fresh SPR buffer and dialyzed overnight at 4°C with gentle stirring.
Dialyzed protein was then removed from the cassette and stored at 4°C until purification
on the FPLC. Prior to loading protein on the FPLC, it was concentrated using Amicon
Ultra centrifugal filter units (Millipore, Billerica, MA). 500 μL of concentrated protein was
loaded onto a Superdex 200 10/300GL and eluted with 1.5 column volumes of buffer.
Fractions were collected, analyzed by SDS-PAGE and saved for surface plasmon
resonance experiments.
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3.2.8 Surface Plasmon Resonance
Protein switch activity was analyzed using surface plasmon resonance. ICAM-Fc
was immobilized at a level of 1220 RU (response units) on a CM5 sensor chip using the
amine coupling kit (BIAcore, Piscataway, NJ). Analytes were flowed over the
immobilized ICAM-Fc at a flow rate of 10 μL/min, 25°C in SPR buffer plus either
scrampep or smMLCKp at 10 μM. Analyte was injected for 240 sec at the following
concentrations: 200 μM, 100 μM, 20 μM, 10 μM, 2 μM, 1 μM, 200 nM, 100 nM and 2
nM. Analyte was dissociated using 20 mM Tris (pH 8), 300 mM NaCl and 20 mM EDTA.
An adjacent flow cell was left empty and blocked and used as a control to subtract bulk
effects. Kinetic analyses were performed using Scrubber2 after subtracting bulk
change and nonspecific binding.
3.3 Results
3.3.1 Circular Permutation
Circular permutation is an efficient method for identifying sites amenable to
domain insertion. This approach has been successfully applied to create a number of
different proteins whose function is allosterically regulated following domain insertion. 16;
19; 97

Following the creation of the circularly permuted I domain library and

transformation into E. coli, seventeen colonies were randomly selected and sequenced
to verify that the library contained full-length, circularly permuted I domain. Out of the 17
sequences, 2 (11.8%) didn‟t contain the I domain gene (i.e., they were re-ligated
vector), 9 (52.9%) contained full-length, circularly permuted I domain sequences, and 6
(35.3%) contained extremely truncated (<40% of total sequence) versions of the gene.
Since the I domain gene with the GGGSG linker is 570 bp the library needs to contain at
least 1615 clones to theoretically sample each DNase I cut site within the gene
assuming that 35.3% of genes remain full-length following the circular permutation. The
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circularly permuted I domain library was transformed into yeast and contained 106
transformants, thereby ensuring that the entire library was adequately sampled.
Clones were initially screened by two rounds of magnetic-activated cell sorting
(MACs) to deplete the library of nonfunctional clones and enrich for binders (Figure 3.3).
The first round of MACS resulted in roughly two-fold enrichment for ICAM binders.
Following the second round of MACS the library was enriched 10-fold over the starting
library for ICAM binders (Figure 3.3). This enriched library was then recovered by
growing in SD-CAA media and sorted by FACS. Following one round of fluorescenceactivated sorting, a population was enriched 17-fold for permutants that retained the
ability to bind ICAM. Twenty clones were then analyzed for their specific ability to bind
ICAM and to determine their new sequence. Interestingly, in all of the permutants that
retain ICAM binding, only changes to their C-terminal allosteric region including the β6α7 loop and the α7 helix were tolerated. Previous studies have shown that the
allosteric region, residues Y257 to E310, of LFA-1 I domain is critical for relaying the
conformational changes of the whole integrin to the active site in order to bind ICAM-1
with high affinity.28; 93 The circular permutation results indicating that this region of the
protein is the most tolerant to changes in its structure, coupled with previous studies
identifying the importance of this region for ICAM-1 binding, led to the design of primers
to focus random mutagenesis in this region.
3.3.2 Directed evolution for improved switches
A library of approximately 1.5 x 107 EF3-I domain-EF4 switch mutants was
created using error prone PCR with 500 μM nucleotide analogs. Four rounds of
fluorescent activated cell sorting (FACS) were conducted to try and isolate a population
of switch proteins whose affinity for ICAM-1 was allosterically regulated by the binding
of an agonist peptide, smMLCK. The naïve library was phenotypically similar to the
wild-type switch where 15.9% and 14.9% of the naïve library bound ICAM-1 in the
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Figure 3.3 MACS enrichment of functional circular permuted I domain library. A)
Naïve library of circular permuted I domain. B) Following a single round of MACS, the
library was enriched by roughly two-fold over the naïve library. C) A second round of
MACS resulted in 10-fold enrichment of functional permuted I domains compared to the
naïve library.
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absence or presence of scrambled peptide, respectively, while 12.9% of the original I
domain-calmodulin fusion, referred to henceforth as wild-type switch, bound ICAM-1 in
the absence of peptide (Figure 3.4 A and B). In the presence of smMLCK peptide,
22.9% of the naïve library bound ICAM-1, similar to the wild-type switch with 23.8%
bound ICAM-1 with smMLCK present. The first round of sorting conducted with 10 μM
smMLCK peptide was used to isolate populations that bound ICAM-1 with increased
affinity. Following the first sort, 42.8% of the library was able to bind ICAM-1 in the
presence of the antagonist peptide (i.e., scrambled peptide) while 47.5% of the library
population bound ICAM in the presence of the agonist peptide (i.e., smMLCKp) (Figure
3.4C). The next two rounds of sorting were considered to be negative sorts where
library expressing yeast that bound ICAM in the presence of 10 μM scrambled peptide
were excluded and only library expressing yeast that didn‟t bind ICAM in the presence
of the scrambled peptide were collected.

Following these two negative sorts, the

library was depleted 30-fold of proteins that bound ICAM in the presence of scrambled
peptide resulting in a phenotypic change in the library population resembling a true offstate (Figure 3.4E). A final positive sort for ICAM binders in the presence of smMLCK
was conducted to enrich the library population that, as a whole, looked to bind ICAM
only in the presence of smMLCK. The final sort resulted in a library population that had
a near 3-fold increase in ICAM binding in the presence of smMLCK compared to ICAM
binding in the presence of scrambled peptide (Figure 3.4F).
Following the final round of FACS, yeast were plated and a total of 50 mutants
were analyzed for switch activity. The majority of clones showed improvements in
switch activity with some mutants displaying as much as a 20-fold increase in ICAM-1
binding in the presence of peptide (Figure 3.5). A few clones demonstrated decreased
ICAM binding in the presence of smMLCKpeptide. Eight of the top clones and four of
the clones that had decreased switch activity were sequenced to identify mutations that
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Figure 3.4 Directed evolution of EF3-I domain-EF4 switch via FACS. Flow cytometry
plots showing both protein surface expression and ICAM-1 binding in the presence of
either smMLCKp (agonist) or the scrambled version of smMLCKP (scrampep,
antagonist). Surface expression is displayed on the vertical axis in mean fluorescence
intensity (MFI) and cells above the horizontal gate can be considered to be expressing
full length switch constructs. ICAM-1 binding is displayed on the horizontal axis in MFI
and cells to the left of the vertical gate can be considered to have proteins binding
ICAM-1. A) Wild-type switch B) Naïve library (i.e., library expressing yeast prior to
sorting) C) Switch library following the first sort with smMLKCp D) Library following a
negative sort in the presence of scrampep E) Library following a second negative sort in
the presence of scrampep F) Library following the last round of sorting; a positive sort in
the presence of smMLCKp.
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Sequenced for improved switch activity
Sequenced for good “off-state”

Figure 3.5 Analysis of individual clones following four rounds of directed evolution for
improved switched. Fifty clones were analyzed for their switching ability relative to the
wild-type switch. Fold change is calculated as discussed in the materials and methods
section. The top 9 clones were sequenced to identify mutations that improved switch
activity in the presence of smMLCKp and three of the lowest switch activity clones were
also sequenced to identify mutations that improved the “off-state” of the switch in the
presence of scrampled peptide.
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both decreased ICAM binding in the presence of the scrambled peptide and increased
ICAM binding in the presence of smMLCKp.
3.3.3 Mutations affecting switch activity
Seventeen unique mutations were found in the twelve mutants that were
sequenced (Table 3.1). Three mutations (L289R, E293A, and Y307D) were found in
multiple mutants, and all were located in either the β6-α7 loop or the α7 helix of the
allosteric region of I domain. Three mutations (I318S, M337V, and K341E) were
located in the EF4 domain of calmodulin. The double mutant, Leu-289-Arg and Tyr307-Asp, was found in three of the seventeen mutants sequenced. Tyr-307 was also
mutated to a serine.

The frequency in which position 307 was mutated highlighted the

need to explore the role of this position in affecting switch activity. A fourth double
mutant, clone 21, which demonstrated decreased switch activity compared to the wildtype switch contained the mutations L289R and I231L. Given the conservative nature
of the isoleucine to leucine mutation, it was hypothesized that L289R is responsible for
locking the switch in a low affinity state. A series of sixteen single, double, triple and
quadruple mutants were created from the mutations found through directed evolution to
try and identify a synergistic set of mutations to further increase switch activity (Table
3.2).
The only single mutant, M8, contained the Leu-289-Arg mutation thought to lock
the switch in a low affinity state. As predicted, M8 saw a decrease in switch activity
relative to wild type switch and lacked the ability to bind ICAM-1 in the presence of
smMLCK peptide (Table 3.2 and Figure 3.6). This mutation was included in the other 15
mutants to improve the off-state of the switch in the presence of scrambled peptide.
Mutants M5, M6, and M7 all contained the EF4 mutation I318S and resulted in
decreased switch activity. Double mutants, M2 and M3, differing in which EF4 residue
was mutated (M337 and K341 for M2 and M3, respectively) showed markedly different
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Table 3.1 Mutations from directed evolution of chimeric switches
Clones

Mutations

Fold Change in ICAM
Binding

Wt

Wild type

2

1

K263R, D290A, Y307D, K341E

8.5

2

Y307S

9

14

M337V

12

20

L289R, Y307D

7

21

L289R, I231L

0.5

22

I258L, E293A

5

29

L289R, Y307D

5

33

V286G

2

34

T273P

5.5

39

E241V, F277C, K280N, I318S

0.5

41

L289R, Y307D

10

44

K252Q, E293A

23
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Table 3.2 Designed point mutations for improved switch activity
Clone

Mutations

Fold Change in ICAM Binding

wt

Wild type

4.4 ± 0.8

M1

L289R, I318S

0.3 ± 0.2

M2

L289R, M337V

11.2 ± 2.8

M3

L289R, K341E

19.9 ± 16.8

M4

L289R, M337V, K341E

8.1 ± 2.5

M5

L289R, I318S, M337V

4.3 ± 2.3

M6

L289R, I318S, K341E

1.9 ± 1.0

M7

L289R, I318S, M337V, K341E

3.6 ± 2.4

M8

L289R

6.8 ± 4.0

M9

L289R, Y307D

11.2 ± 3.2

M10

L289R, Y307S

10.3 ± 5.7

M11

L289R, Y307D, M337V

2.0 ± 1.0

M12

L289R, Y307S, M337V

94.3 ± 28.7

M13

L289R, Y307D, K341E

31.1 ± 12.9

M14

L289R, Y307S, K341E

33.4 ± 11.6

M15

L289R, Y307D, M337V, K341E

68.0 ± 30.7

M16

L289R, Y307S, M337V, K341E

124.1 ± 113.3
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Figure 3.6 Mutant switch activity measured by flow cytometry.
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switch activities indicating that M337V is likely more beneficial than K341E is to
improved switching. The effect of these two mutations is also seen when comparing
M12 and M14. Comparing M11 to M12, M13 to M14 and M15 to M16, it appears that
Y307S is more beneficial than Y307D to improving switch activity. Two of the three
mutations of the EF4 domain, M337V and K341E, likely increase the specificity of the
EF hands for smMLCKp in relation to scrambled peptide. The third mutation, I318S, is
thought to disrupt the hydrophobic pocket created by the two EF hands in which Trp799 of smMLCK peptide is buried. This disruption of the hydrophobic pocket by
substitution with a polar residue diminishes peptide binding and therefore switch activity.
3.3.4

Effect of peptide concentration on switch activity
The effect of peptide on switch activity was tested by incubating the wild-type

switch and one of the top performing switches, M12, with differing concentrations of
smMLCK and scrambled peptide. Peptide concentrations ranging between 200 nM and
200 μM were tested. At concentrations of smMLCK peptide above 100 μM the amount
of ICAM-1 bound by both switches increases significantly and both wild-type and M12
switches bind ICAM-1 with similar affinities in the presence of 200 μM smMCK peptide
(Figure 3.7). However, a noticeable difference in ICAM-1 affinity is seen between the
two switches in the presence of the scrambled peptide. Scrambled peptide at 200 μM
causes about at 40% increase in ICAM-1 binding with the wild-type switch compared to
switch M12 (comparing ICAM-1 binding fluorescence intensity at 200 μM with
scrambled peptide). Similarly, the fluorescence intensity associated with ICAM-1
binding in the presence of the scrambled peptide is consistently lower across all peptide
concentrations with the M12 switch compared to the wild-type switch. The lowered
affinity also increases the dynamic range of the M12 switch allowing for improved switch
activity.
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Effect of Peptide Concentration on ICAM-1
Binding
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Figure 3.7 Effect of peptide concentration on switch activity. Wild-type (A) and M12 (B)
switches were incubated with peptide at final concentrations between 200 nM and 200
μM and ICAM-1 binding was measured by flow cytometry. Mean fluorescence intensity
from ICAM-1 binding was plotted against peptide concentration and curves were fit
using Prism.
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3.3.5 Soluble protein analysis
To accurately determine binding affinities for the engineered switches, as well as
rule out any artifacts due to the surface display construct, soluble switches were
produced for binding kinetics analysis using surface plasmon resonance. ICAM-Fc was
immobilized on the sensor surface of a CM5 chip and switches in the presence of 10
μM smMLCK or scrambled peptide were flowed over the senor surface and ICAM-1
binding was measured in real time. Affinity measurements for a first generation switch,
Switch 9, was found to be 132 μM in the presence of smMLCK peptide and 550 μM in
the presence of scrambled peptide (Table 3.3 and Figure A10.1). This 4.2-fold change in
ICAM binding in the presence of the effector peptide, smMLCK, is consistent with what
has been observed by flow cytometry with this switch. Additionally, by inspection of
ICAM binding by flow cytometry reveals that this switch likely has low to „intermediate‟
ICAM-1 affinity based on comparison between high affinity and low affinity I domain
controls. Additionally, comparison of the kon and koff for this switch are consistent with
previously measured association and dissociation rate constants for different I domain
mutants regarded as having intermediate ICAM affinities.93 I domain mutants from this
study had reported kon between 133 x 103 and 3.4 x103 M-1 s-1, koff between 0.43 and 1.2
s-1, and KD between 3.0 and 450 μM for intermediate to low-intermediate affinity I
domain mutants.93
3.4 Discussion
Previous work has developed an allosteric switch by fusing the EF3 and EF4
hands of calmodulin to the N- and C-termini of I domain, respectively, resulting in a
chimeric fusion protein with a modest two-fold increase in ICAM-1 binding in presence
of smMLCK peptide .89 This work sought to improve the switch activity of the initial
switch construct, herein referred to as the wild-type switch, by improving the off-state of
the fusion protein through directed evolution (i.e., minimize ICAM-1 binding in the
absence of peptide/presence of scrambled peptide) while retaining ICAM-1 binding at
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Table 3.3 Binding kinetics of soluble switches

Switch

Peptide

kon (M-1·s-1 x 10-3)

koff (s-1)

KD (μM)

SW 9

scrambled

0.96 ± 0.5

0.48 ± 0.05

550 ± 220

SW 9

smMLCK

2.7 ± 0.8

0.34 ± 0.05

132 ± 15

SW 1

scrambled

1.0

0.57

570

SW 1

smMLCK

1.2

0.22

190

Fold
Change

4.2

3.0
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near wild-type levels in the presence of smMLCKpeptide. Previous studies have shown
the power of combining circular permutation and domain insertion to create protein
fusions that effectively couple β-lactamase activity to the presence of maltose.97 Our
first approach to improving the switch activity of the EF3-I domain-EF4 construct was to
create and screen a library of circularly permuted I domains to identify a non-obvious
site within the I domain structure that would be amenable for domain insertion.
Interestingly, only new termini in the allosteric region of the I domain were tolerated.
This finding was significant in two ways. First, it reiterated the importance of this part of
the I domain in controlling ICAM-1 binding through allosteric rearrangements in the I
domain, reaffirming previous findings.28; 93 Second, it provided a site to focus
mutagenesis to try and introduce mutations that could improve the switch activity of an
EF3-I domain-EF4 fusion. As the β6-α7 loop is displaced by the downward movement
of the α7 helix, three residues, Leu-295, Phe-292 and Leu-289, located along the β6-α7
loop occupy a hydrophobic pocket in succession as the I domain goes from a closed, to
an intermediate, to an open conformation, respectively. Additionally, the movement of
the α7 helix and the β6-α7 loop disrupts the hydrophobic core of the protein along with a
network of hydrogen bonds within the central β-sheet structure of the I domain, this
disruption causes rearrangements of loops containing MIDAS coordinating residues
bringing the MIDAS residues into a high affinity conformation and completing
transmission of the allosteric signal from the allosteric region to the ICAM-1 binding site
of the MIDAS.28; 93; 102 Prior to performing focused random mutagenesis on the
allosteric region of the protein, a fusion was constructed where the α7 helix of the I
domain was replaced by a short GGG linker connecting the EF4 hand directly to the
allosteric region of the I domain to hopefully cause a greater disruption of the allosteric
region upon peptide binding. However, this construct resulted in negligible
improvement in switch activity necessitating the need for focused random mutagenesis
(data not shown).
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The mutation, Leu-289-Arg, which appeared in four of the clones, three of which had the
identical double mutation of Leu-289-Arg and Tyr-307-Asp, is critical for improved
switching. Upon examination of the low affinity crystal structure of the αL I domain Arg289 likely forms a salt bridge with residue Glu-301 (Error! Reference source not
found.). A salt bridge prevents the transition from a low affinity conformation to a high
affinity conformation, thus locking the α7 helix in place and preventing the I domain from
binding ICAM-1. Clone M8, which contained the single mutation L289R did indeed
show negligible ICAM-1 binding confirming that Leu-289-Arg does keep the I domain in
a low affinity conformation.
Two amino acids that are beneficial to improved switch activity, aspartic acid and
serine, were found in place of the wild-type tyrosine at position 307. Both aspartic acid
and serine are much smaller than tyrosine and position 307 is the last I domain residue
prior to a short linker and the EF4 hand on the C-terminal end of the fusion. The
smaller side chains of aspartate and serine may provide the EF4 hand more flexibility
allowing the EF4 to adopt a large range of conformations to improve smMLCK peptide
binding. Furthermore, it appears that shorter is better. Comparing mutants where the
only difference is whether Tyr-307 has been changed to an aspartate or serine, mutants
with the shorter serine side chain mutation have marked improvement in switch activity.
The two mutations associated with the EF4 hand that improve the switch activity
of the fusion are M337V and K341E. Each of these mutations probably contributes to a
number of small beneficial interactions and cumulatively these interactions increase the
affinity of the EF4 hand for the effector peptide. The smaller side chain of valine likely
allows for tighter packing of Trp-799 of the peptide into the hydrophobic pocket of the
EF4 hand strengthening the hydrophobic interaction between the peptide and EF4.
Similar electrostatic interactions between the mutated Lys-341-Glu and the positively
charged N-terminus of the peptide contribute to improved binding of the EF-hands to the
79

Figure 3.8 L289R mutation creates an ion pair with Glu-301. The Leu-289-Arg
mutation was modeled into the low affinity I domain crystal structure (PDB 1LFA) using
Swiss-PdbViewer (http://www.expasy.org/spdbv/)103 and the rotamer with the lowest
score was selected. The L289R mutation was then analyzed in PyMol and determined
to make an ion pair with Glu-301 of the α7 helix. Amino acid side chains are shown as
ball and stick with Arg-289 in purple and Glu-301 in orange.
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peptide. The N-terminus of smMLCK peptide is littered with positively charged residues
providing ample opportunity for attractive charge-charge interactions to occur between
the positively charged N-terminus of the peptide and the negatively charged glutamic
acid. The magnitudes these mutations have on improved switch activity are likely very
similar as neither M337V or K341E clearly outperforms the other mutation. Thus, the
effect of either of these mutations in combination with Y307S and L289R improve the
switch activity of the protein.
Taken together, mutant M12, which contains L289R, Y307S and M337V
mutations, was consistently the best performing switch. The effects of the different
mutations seem to indicate that L289R provides a stabilizing force maintaining the I
domain in a closed conformation. Presumably, binding of the EF3 and EF4 hands to
smMLCK peptide sufficiently disrupts the salt bridge between L289R and E301 allowing
the I domain to relax into a higher affinity conformation. The overall effect is that, in the
presence of scrambled peptide, the EF3 and EF4 hands do not associate strongly
enough to disrupt the Arg-289–Glu-301 salt bridge providing a true, low affinity state for
the switch. In the presence of smMLCK peptide, the EF3 and EF4 hands are able to
associate strongly enough to disrupt the salt bridge and allow the switch to adopt a
higher affinity conformation.
We have demonstrated the ability to use directed evolution to improve the switchlike functionality of a fusion between the LFA-1 I domain and the EF3 and EF4 hands of
calmodulin. Previous work had developed this fusion as the first example of a protein
switch where the controlled output function was adhesion. The use of circular
permutation allowed for the identification of a key structural region of the I domain, the
allosteric region, providing some rational design guidance in subsequent directed
evolution work. Through focused mutagenesis on the switch-allostery region of the
protein a complementary set of mutations both in the allosteric region of the I domain
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and the EF4 hand of calmodulin contribute to a near 20-fold improvement over the
original, fusion construct. Particular detail was paid to identifying mutations that
provided the switch an improved „off-state‟, a key in engineering any protein switch, and
identification of the L289R mutation was critical to improving the off-state of the protein
and providing an improved dynamic range of switch activity over the original switch.
The ability to use directed evolution to identify mutations to rapidly improve desired
functionality of any protein, as well as to probe the structure-function relationship and
provide guidance for protein engineering, further illustrates the power of this approach.
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Chapter 4 : Directed evolution for altered peptide specificity
4.1 Introduction
Protein engineering has evolved from trying to better understand enzymes to a
field focused on not only gaining insight into biological processes but also developing
proteins for industrial and therapeutic applications.104; 105 Protein allostery, the
reversible conformational change of a protein by regulation of an effector molecule at a
site distinct from the active site of the protein, has been a major theme in understanding
gene regulation, metabolic pathways, and protein structure and function over the last 50
years. 10; 106; 107 In fact, a number of current drugs, such as valium, exploit allosteric
perturbations, thereby „locking-in‟ a specific conformation and providing a therapeutic
effect to the cell.108 Allosteric drugs have the ability to modulate protein activity without
completely eliminating it, can be used in combination with drugs that target other sites to
provide an increased, beneficial effect, and tend to be highly specific for their binding
site.109 Specifically, drug discovery research efforts have demonstrated that G-proteincoupled receptors (GPCRs) can be positively and negatively modulated by synthetic
ligands.110; 111 Additionally, the ability to provide requisite effector molecules for an
allosteric protein to function provides another layer of specificity that could be
advantageous in a drug delivery or molecular imaging capacity.
Our lab has previously demonstrated the first example of a chimeric, adhesive
switch that increases affinity in the presence of an activating peptide.89 The I domain,
located at the membrane distal end of the α subunit of the integrin LFA-1, contains the
entire ligand binding site of the macromolecule. Through inside-out signaling the
integrin is activated and begins to refold from its low-affinity, bent conformation into an
extended conformation resulting in the axially downward displacement of the C-terminal,
α7 helix of the I domain by about 10 Å. The downward movement of the α7 helix of the
I domain acts as a pulley causing a rearrangement of the metal ion-dependent adhesion
83

site (MIDAS) drastically altering the affinity for the ligand, ICAM-1.9; 11; 92; 95 The I
domain served as an ideal candidate for a protein switch as the natural allosteric
movement of the protein, typically induced by the surrounding domains of the LFA-1
integrin, could be induced by a second protein fused to the I domain. This was
accomplished by fusion of the EF3 and EF4 hands of calmodulin to the N- and C-termini
of the I domain, respectively.
Calmodulin (CaM) is an ubiquitous Ca2+ sensing protein that binds a number of
different target proteins, including smooth muscle myosin light chain kinase (smMLCK).
The TR2C domain of CaM, composed of EF3 and EF4 hands, binds smMLCK peptide
with an affinity of 80 nM.98 The EF3 and EF4 hands have also demonstrated the ability
to recombine in the presence of a 20 residue peptide of smMLCK in solution.98 The
binding of smMLCK by CaM, along with a number of other peptides, has been well
characterized and classified based on their sequence motif. 112; 113 The smMLCK peptide
used in these studies resides in the 1-14 class of CaM target proteins and more
specifically the subclass, basic 1-8-14.112 Target peptide classes are defined by the
location of consensus hydrophobic residues. In the basic 1-8-14 subclass, three basic
residues precede a consensus hydrophobic residue. This is followed by another
hydrophobic residue seven amino acids later, followed by a basic residue five amino
acids later which is immediately followed by the final consensus hydrophobic amino
acid. In Chapter 3, a scrambled version of smMLCK was used as a negative control.
Importantly, the scrambled version of smMLCK contained significantly different residues
at the key locations within the basic 1-8-14 motif (Table 4.1). The differences in amino
acid composition at these locations between the two peptides allowed for the binding of
smMLCK and the inability to bind scrambled peptide, and it is these differences that will
be exploited to alter the peptide specificity of our switches.
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Table 4.1 Peptide sequences

Peptide Name

Sequence*

smMLCK

ARRKWQKTGHAVRAIGRLSS

scrambled smMLCK
(“scram”)

LVARHIKSSTRRAGGKAWRQ

* Basic 1-8-14 sequence ( β β β φ - - - - - - φ - - - - β φ - - -),
where β represents a basic residue and φ represents a hydrophobic residue. The key
hydrophobic locations are shown in bold.
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The initial fusion construct, referred to as wild-type switch, had a near 2-fold
change in ICAM-1 binding in the presence of the smMLCK peptide compared to ICAM-1
binding in the absence of peptide.89 The protein switch was then further engineered
using directed evolution in Chapter 3 to improve the switch activity of the protein 20-fold
over the original switch. To make an adhesive switch of this nature more viable for
eventual applications the ability to alter the specificity of the effector peptide is critical.
To this end, we show that it is possible via directed evolution to alter the peptide
specificity of a previously engineered I domain-EF hands switch such that the switch
now responds to peptide that had previously served as a negative control.
Demonstrating the ability to manipulate a complicated protein switch to respond to
different effector peptides makes it amenable for a wide array of applications and
environments where the specificity of the effector peptide could be tailored to a specific
application.
4.2 Materials and Methods
4.2.1 Yeast strains and plasmids
S. cerevisiae EBY100 (MATa AGA1::GAL1-AGA1::URA3 ura3-52 trp1 leu2Δ1
his3Δ200 pep4::HIS3 prb1_1.6R can1 GAL) cells were transformed with pCT302derived vectors allowing for selection under Trp- and Ura- conditions and surface
expression of proteins under the galactose inducible GAL1,10 promoter.99 pCT302 was
used as the expression vector and fusion constructs were cloned in using NheI and
BamHI restriction sites. Use of NheI and BamHI restriction sites allows two epitope tags
(HA or c-myc) on either side of the gene of interested to be expressed in the
ORF.

Yeast were grown in the semi-defined media SD-CAA (20g/L dextrose, 6.7 g/L

yeast nitrogen base without amino acids, 5.4 g/L Na2HPO4, 9.7 g/L NaH2PO4·H2O, and
5 g/L CAA) at 30°C overnight. The following day, expression was induced by
subculturing at an OD600 of 1 and grown overnight in SGR-CAA (same as SD-CAA
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except 2% (w/v) dextrose is replaced with 2% (w/v) galactose and 2% (w/v) DRaffinose).
4.2.2 Flow cytometry
Yeast were grown and induced as previously described in section 3.2.1.
Following overnight induction in SGR-CAA at 30°C, 3x106 cells (OD600 of 0.3) were
transferred to microcentrifuge tubes for washing and immunofluorescent labeling. Yeast
were washed twice with 500 μL Labeling Buffer (137 mM NaCl, 2.7 mM KCl, 10mM
Na2HPO4, 2mM KH2PO4, 10 mM MgCl2, and 1 mM CaCl2). Following the washes, cells
were incubated with mouse anti-c-myc antibody 9E10 (ascites fluid, Covance,
Princeton, New Jersey) at a 1:100 dilution in Labeling Buffer for 45 to 60 minutes at 4°C
along with either smMLCK peptide or a scrambled version of smMLCKp (henceforth
referred to as „scrampep‟) at a concentration of 10 μM. Yeast were washed once with
500 μL of Labeling Buffer then resuspended in 30 μL for labeling with fluorescent
secondary antibodies and precomplexed ICAM-Fc/anti-Fc AF647. 1.5 μL of ICAM-Fc
per sample (200 μg/mL) (R&D Systems, Minneapolis,MN) was precomplexed with Alexa
Fluor 647-conjugated goat anti-human anti-Fc secondary antibody (Jackson
ImmunoResearch, West Grove, PA) at a ratio of 1:1.6 at 4°C for at least 60 minutes.
Yeast were costained with precomplexed ICAM-Fc/AF647 anti-Fc, at a final ICAM-Fc
concentration of 10 μg/mL, goat anti-mouse Alexa Fluor 488 (Invitrogen) at 1:100 and
smMLCKp or scrampep at room temperature, protected from light for 1-2 hrs. Following
the secondary incubation, yeast were spun down at 10,000xg for 1 minute and
resuspended in 1 mL of fresh Labeling Buffer. Samples were analyzed on an Accuri C6
flow cytometer (BD Biosciences, Ann Arbor, MI). 10,000 events were collected per
sample and gated based on size. Background-corrected mean AF647 fluorescence
(i.e., ICAM-1 binding) was normalized by background-corrected mean AF488
fluorescence (i.e., full length protein surface expression). Normalized mean
fluorescence of ICAM-binding of samples incubated with smMLCKp was divided by
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normalized mean fluorescence of ICAM-binding of samples incubated with scrampep to
calculate a fold-change in ICAM binding. The following equations outline the foldchange calculations:

NMFI

MFI 647 sample

MFI 647bkgd

MFI 488sample

MFI 488bkgd

Fold Change

NMFI smMLCKp
NMFI scrampep

where NMFI is the normalized mean fluorescence intensity, MFI 647sample is the mean
fluorescence intensity due to ICAM-binding by the sample protein , MFI647bkgd is the
mean fluorescence intensity of ICAM binding by a negative control population
expressing a disparate protein on the yeast surface, MFI 488sample is the mean
fluorescence intensity of protein expression by the sample protein and MFI 488bkgd is
the mean fluorescence intensity of protein expression by uninduced yeast.
4.2.3 Peptide specificity library construction
Saturation mutagenesis via overlap extension PCR was used to change seven
residues thought to participate in the binding of smMLCK peptide. NNK codons were
used to randomize the seven amino acids in the EF3 and EF4 hands. Four primers
were used to create the library (Table 4.2). Briefly, the primers encoded for mutations
at key residues using NNK codons and both primers in each direction contained 20 bp
of homology with each other to ensure efficient overlap of the gene PCR products. The
„outside‟ primers also contained 50 bp of homology to the pCT302 vector for
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Table 4.2 Peptide specificity library primers

Primer Mutations
Name Encoded

Sequence*

Inside
Forward

L105X

5‟-cgagaggcgttccgtgtctttgacaaggatgggaatggctacatcagcgccgcagagNNKcgtcaccgaatgacgaac-3‟

Outside
Forward

E84X

5‟-gctagtggtggtggtggttctggtggtggtggttctggtggtggtggttctgctagcagtgaggagNNKatccgagaggcgttccgtgtcttt-3‟

Inside
Reverse

M124X
E127X
A128X

Outside
Reverse

M144X
K148X

5‟-aaactcttcataattgacctggccatctccatcgatgtcKNNKNNcctgatKNNctcatccacctcctcatc-3‟

5‟-ttatcagatctcgagctattacaagtcctcttcagaaataagcttttgttcggatccKNNtgcagtcatKNNctgtacaaactcttcataattgacctg-3‟

* Homologous sequences between both „inside‟ primers and both „outside‟ primers are underlined.
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homologous recombination in yeast. The „inside‟ primers were used to carry out the
initial PCR reaction using 50 ng of the M12 switch gene as the template DNA with 2.5
units of Taq DNA polymerase (NEB, Ipswich, MA), primers at a final concentration of
200 nM each, 5 μL of 10X Standard Taq Reaction Buffer (NEB), 1 μL of dNTPs (10
mM), 2 μL of MgCl2 (25 mM), and dH2O to a final reaction volume of 50 μL. The PCR
reaction had the following steps: 1) 68°C for 2 min 2) 95°C for 30 seconds 3) 68°C for
30 seconds 4) 68°C for 50 seconds, 5) repeated steps 2-4 30 times 6) 68°C for 5
minutes 7) hold at 4°C. The PCR product was analyzed on a 1% agarose gel and
purified using the Wizard SV gel and PCR clean-up system (Promega, Madison, WI)
following the manufacturer‟s instructions. The purified PCR product was then used as
the DNA template for the second PCR and was performed as just described with the
only exception being the total volume of the reaction was increased to 1 mL. The
second, full length PCR product was again analyzed and purified as described. Purified
DNA was then concentrated using Pellet Paint Co-precipitant (EMD Millipore, Billerica,
MA) following the manufacturer‟s instructions. Homologous recombination using 50-bp
of homology on each side of the NheI and BamHI restriction sites allowed for efficient
recombination of the library into the linearized pCT302 expression vector. Seven
electroporations, each with 3 μg of library DNA and 125 ng of linearized vector, were
pooled together and transformed yeast were allowed to recover in YPD (2% w/v
dextrose, 2% w/v peptone, and 1% w/v yeast extract) for 1 hr at 30°C. The transformed
yeast library was then centrifuged at 1,000xg for 3 minutes and resuspended in 10mL of
SD-CAA and serial dilutions were plated. Following three days growth at 30°C colonies
were counted on the serial dilution plates and library size was estimated to be 2x106
4.2.4 Fluorescence-activated cell sorting
The library was sorted a total of four times using alternating rounds of positive
and negative selections to enrich for yeast that displayed switching behavior in
response to the presence of the scrambled peptide. The first two rounds of library
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sorting were positive selections to enrich for a population that bound ICAM-1 in the
presence of 100 μM scrambled peptide. The third round was a negative sort to deplete
the library of yeast that bound ICAM-1 in the presence of smMLKC peptide at 100
μM. The fourth round of sorting was a positive sort to re-enrich for ICAM-1 binders in
the presence of 100 μM scrambled peptide. Library expressing yeast were grown and
induced as previously described. Following overnight induction at 30°C for at least 20
hours, 3.5x107 cells (OD600 = 3.5) were aliquoted and immunostained as previously
described. Briefly, cells were washed with Labeling Buffer then labeled with anti-c-myc
mouse monoclonal antibody, 9E10 (Developmental Studies Hybridoma Bank, University
of Iowa) at a dilution of 1:50 for 1 hour on ice. During the primary incubation, library
expressing yeast were incubated with either 10 μM smMLCK peptide or 100 μM
scrambled smMLCK peptide. Following the primary incubation, cells were washed with
Labeling Buffer then labeled with precomplexed ICAM-1-Fc/anti-Fc AlexaFluor 647,
smMLCKp at 10 μM or scrampep at 100 μM, and goat anti-mouse AlexaFluor 488 at a
1:100 dilution.
4.3 Results and Discussion
4.3.1 Library specificity construction
The key interacting residues of smMLCK peptide are Arg-797, Lys-799 and Arg812, which are involved in the formation of salt bridges, and Trp-800, which has its large
hydrophobic side chain buried in a hydrophobic pocket created by the EF3 and EF4
hands.113; 114 Multiple residues of EF3 and EF4 make contacts with the charged and
hydrophobic residues of smMLCK providing attractive electrostatic interactions and a
hydrophobic pocket for Trp-800CaM. Residues Leu-105MLCK, Met-124 MLCK, Ala-128 MLCK,
M144 MLCK all interact with Trp-800 CaM via hydrophobic interactions (Figure 4.1). Glu127 MLCK is thought to make salt links with Arg-797 CaM and the α-amonium group of Ala796. Met-124 MLCK also provides interactions to the side chain of Ala-796 CaM and Lys799 CaM, while M144 MLCK has van der Waals contacts with Gln-801 CaM. Glu-84 MLCK of
91

E127
M124
A128
L105

M144
W800

R812

E84

Figure 4.1 Key residues of the smMLCK and CaM interaction. Key positions chosen
for site-saturation mutagenesis were chosen based on literature112; 114 as well as
analysis of the structural rendering of the interaction between the two proteins. Here,
key residues thought to be important for smMLCK (magenta) binding by calmodulin
(PDB 1CDL) EF3 (light blue) and EF4 (dark blue) are shown as ball and stick. Ca2+
bound by the EF hands are shown as black spheres. W800 of smMLCK is buried in a
hydrophobic pocket created by EF3 and EF4. R812 of smMLCK forms an ion pair with
E84 of EF3 of CaM.
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EF3 forms a salt bridge with Arg-812 CaM of the peptide providing additional attractive
forces for the binding of the smMLCK peptide to the EF hands of calmodulin. Finally, in
previous work using random mutagenesis to improve the switch activity of our EF-I
domain protein switch, Lys-148 MLCK was found to be a beneficial mutation in a number
of clones. While Lys-148 MLCK is located at the extreme C-terminal end of the EF4 hand
its frequency of mutation in previous experiments led to the conclusion that it likely
provides some importance to binding of smMLCK peptide and was therefore included in
the mutagenesis strategy presented here.

The large number of interactions contributing to the binding of smMLCK by the
EF hands due to just seven amino acids, out of 64 total residues in the binding cleft
created by the EF hands, seemed to indicate that heavy mutagenesis of these residues
could provide sufficient enough change to be able to switch the peptide specificity of the
calmodulin domain. It was reasoned that by essentially abolishing binding to the
smMLCK peptide, a set of mutations allowing for binding to a scrambled version of
smMLCK peptide, which had previously served as a negative control in switch
experiments, could come to light. Site-saturation mutagenesis using NNK degenerative
codons and nested PCR (Table 4.2) was used to try and sample all possible amino
acids at each of these seven positions since it was impossible to know which residues
in the EF hands would impart new specificity. The theoretical size of the library is
1.3x109 which is on the cusp of yeast transformation efficiency limits.115 Factoring the
biased representation of amino acids due to the NNK codon, the actual theoretical size
of the library would be greater than 1.3x109 pushing the attainable size of a library
outside the window of yeast transformation efficiency. The estimated size of the library
produced for screening changes in peptide specificity was calculated to be 2x10 6
therefore under-sampling the entire sequence space that would like to be explored, but
likely large enough to produce mutants with the desired characteristic of altered peptide
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specificity. Further directed evolution and affinity maturation could be used later to
produce additional diversity and identify a set of mutations that improve the specificity of
the EF hands for the scrambled peptide.
4.3.2 Library Screening
Similar to the sorting performed in Chapter 3 for improving the EF3-I domain-EF4
switch, four rounds of sorting were used to screen the library for mutants with altered
peptide specificity. Alternating positive (in the presence of 100 μM scrambled peptide)
or negative (in the presence of 30 μM smMLCK peptide) sorts were performed to drive
the library population towards a phenotype that selectively bound ICAM-1 in the
presence of scrambled peptide and didn‟t binding ICAM-1 in the presence of smMLCK
peptide. The naïve library showed negligibly better ICAM-1 binding in the presence of
scrambled peptide (31.6%) than in the presence of smMLCK peptide (30.6%) (Figure
4.2 A). Given the shift in FL4 fluorescence (X-axis) in the non-expressing population in
the presence of 100 μM scrambled peptide, the slight one percent increase in ICAM-1
binding is likely due to background. Therefore, it can be assumed that the naïve library,
as a whole, had no specific preference for smMLCK or scrambled peptide at the outset
of sorting. The first round of fluorescence-activated cell sorting (FACS) resulted in a
5.5% increase in cells that bound ICAM-1 when incubated with 100 μM scrambled
peptide compared to cells expressing switches that bound ICAM-1 when incubated with
10 μM smMLCK peptide (Figure 4.2 B) Following the second sort collecting switches
that had been incubated with 100 μM scrambled peptide the library population was
enriched by only about 2% for mutants that preferred scrambled peptide over switches
that preferred smMLCK indicating that non-specific ICAM-1 binders had also been
selected (Figure 4.2 C). A third, negative sort in the presence of 30 μM smMLCK was
used to remove library members that either bound ICAM-1 regardless of the peptide
present or bound ICAM-1 in the presence of smMLCK. A higher concentration of 30 μM
of smMLCK peptide, compared to 10 μM which is the concentration routinely used in
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Figure 4.2 Peptide specificity library at different stages of FACS. Two color
immunofluorescent staining of the peptide specificity library where fluorescence
intensity on the vertical axis represents the amount of full-length surface expressed
library protein and fluorescence intensity on the horizontal axis represents the amount
of bound ICAM-1 in the presence of the indicated peptide. A) The naïve library with no
peptide, 10 μM smMLCK peptide (PEP), or 100 μM scrambled smMLCK (SCRAM). B
and C) The library following the first and second rounds of sorting, respectively, in the
presence of 100 μM scrambled peptide. D) The library population following a third sort
in the presence of 30 μM smMLCK peptide to deselect non-switching binders and a
fourth round of sorting in the presence of 100 μM scrambled peptide.
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Figure 4.2 Continued
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our switch assays, was used to increased the selective pressure for switches that
selectively bound scrambled peptide. A final, positive sort in the presence of 100 μM
scrambled peptide was used to re-enrich the library population that responded to the
presence of scrambled peptide by binding ICAM-1. This final sort resulted in a near 5%
increase in ICAM-1 binding when the mutant switches are incubated with scrambled
peptide compare to smMLCK peptide (Figure 4.2 D). Following the fourth round of
sorting, the library was plated on SD-CAA medium and random colonies were screened
for switch activity in the presence of scrambled peptide.
4.3.3 Screening of individual mutants for altered specificity
A total of 58 mutants were screened for altered peptide specificity by calculating
the raw (no background correction) fold change in ICAM-1 binding in the presence of
scrambled peptide over the presence of smMLCK peptide (Figure 4.3). No background
correction was applied in these calculations since there is minimal ICAM-1 binding in
the presence of smMLCK peptide and subtraction of background fluorescence can
result in negative values skewing the effectiveness of the switch. The average fold
change in ICAM binding in the presence of scrambled peptide versus smMLCK was
calculated for the wild-type switch and found to be 1.48. Since the wild-type switch has
been shown repeatedly to respond to smMLCK peptide the expected value for switch
activity for this switch should be less than unity (i.e., specificity for smMLCK over
scrambled peptide). The elevated switch activity of the wild-type protein is likely due to
some non-specific interactions due to the 10-fold high concentration of scrambled
peptide compared to smMLCK. In other words, had both peptide concentrations been
increased to 100 μM for the wild-type switch, the switch would still respond selectively to
smMLCK as was seen in the peptide titration experiments from Chapter 3.
Nevertheless, any switches that demonstrated a fold change greater than 1.48 were
considered to have altered peptide specificity.
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Figure 4.3 Screen of peptide specificity mutants for switch activity. Fifty-eight (58)
mutants were randomly screened at least once to determine their switch activity in
response to scrambled peptide. Mutants that proved promising after the initial screen
(red) had their plasmids rescued from yeast and were retransformed into yeast to
confirm that the phenotype transferred.
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Eight switches, mutants 10, 26, 31, 44, 45, 48, 54, 56, 58, met or exceeded this
threshold for switch activity and a ninth, mutant 26, looked qualitatively similar to these
mutants and was also chosen for further examination. Curiously, mutants 10, 26, and
31 lacked non-expressing yeast populations (i.e., the population always located in the
lower left quadrant of two-color flow cytometry plots due to plasmid loss) meaning that
the gene was likely integrated into yeast genomic DNA complicating plasmid recovery.
Plasmids were recovered for mutants that exhibited the negative population and
phenotypes were confirmed to transfer with the plasmid.
4.3.4 Mutations affecting peptide specificity
Sequencing analysis revealed a total of 17 unique mutations in the EF3 and EF4
hands of five different mutants whose plasmids were successfully recovered. The
majority (13/17) of these mutations were located at targeted residues (E84, L105, M124,
E127, A128, M144, and K148) (Table 4.3). Two mutants, 54 and 58, had identical sets
of eight mutations; E84D, R106C, D118N, M124F, E127L, A128H, M144I and K148Y.
Additionally, four spontaneous mutations arose through the rounds of directed evolution
and were identified by sequencing: E87Q, R106C, D118N and Q143R. Three out of
the four spontaneous mutations are charged residues indicating the importance of
electrostatic interactions in peptide binding. More interesting, however, is that both
R106C and D118N always occurred together. In the native calmodulin-smMLCK
complex, these two side chains which are located on EF3 and EF4, respectively, form
an ion pair with each other stabilizing the complex and presumably assist in effecting
the switch activity of the molecule (Figure 4.4). Taking either mutant 54 or 58 as an
example of a set of mutations needed for altered specificity some general conclusions
about altering specificity can be made. Both mutants had five charged residues and
three hydrophobic residues at the outset of the directed evolution study. Following the
four rounds of sorting for altered specificity, these mutants retained a negatively
charged residue (E84D) and two hydrophobic residues (M124F and M144I) at the same
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Table 4.3 Mutations found in altered peptide specificity mutants
Mutant

EF3 Mutations

EF4 Mutations

10

E87Q

Q143R

48

E84C

54

E84D R106C

D118N M124F E127L A128H M144I K148Y

56

E84G L105V

M144T K148R

58

E84D R106C

D118N M124F E127L A128H M144I K148Y

M124S

A128G M144T K148Y

Note: Mutations highlighted in red arose spontaneously
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D118
R106

Figure 4.4 Stabilizing effect of Arg-106 and Asp-118. In native calmodulin (PDB 1CDL)
complexed with smMLCK peptide (magenta), Arg-106 located on the C-terminal half of
EF3 (light blue) and Asp-118 on the C-terminal half of EF4 (dark blue) form a salt
bridge.
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positions. A fourth mutation (D118N) by itself is a relatively conservative change, but
coupled with the R106C mutation could have a significant role in altering specificity.
Namely, without the additional stabilizing interaction of the Arg-106-Asp-118 salt bridge
the EF3 and EF4 hands may be able to associate more freely and bind the scrambled
peptide in a different orientation than the smMLCK peptide. Finally, three positions
(E127L, A128H, and K148Y) experienced drastic changes going from charged residues
to hydrophobic residues or vice versa. These mutations could provide adequate
enough rearrangement of hydrophobic and charged residues within the EF hands to
accompany the changes in distribution of charged and hydrophobic residues of the
scrambled peptide.

Together, the rearrangement of charged and hydrophobic

residues along with the possible additional flexibility afforded by the double R106C and
D118N mutations may provide the right combination of changes for the switch to bind
ICAM-1 in response to the scrambled peptide.
4.4 Conclusion
To expand this technology further towards being commercially viable, it is
important to demonstrate the design flexibility available in constructing a protein switch
of this nature. The ability to engineer a protein switch to respond to a new effector
molecule has been attempted many different times with varying degrees of success.17;
85; 116; 117

Previously, this fusion protein had been engineered to demonstrate about a

70-fold increase in ICAM-1 binding in the presence of smMLCK peptide compared to a
scrambled version of smMLCK. In this study, as a proof-of-concept, we flipped the
specificity of the effector peptide for the switch protein from smMLCK to the scrambled
peptide. Five mutants isolated after four rounds of directed evolution and fluorescenceactivated cell sorting (FACS) showed a roughly 2-fold increase in ICAM-1 binding in the
presence of scrambled peptide compared to smMLCK. While this is a very modest
switching activity, additional directed evolution could be used to further improve the
activity of the switch by improving the affinity of the EF3 and EF4 hands for the
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scrambled peptide. Tighter binding of the scrambled peptide by the calmodulin domains
would likely improve the switch function of the protein by providing a greater
perturbation in the allosteric region of the I domain.
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Chapter 5 : Summary and Recommendations
5.1 Summary
The ability of proteins to change their shape allows them to perform their unique
functions. Here, we have studied two proteins which undergo conformational
rearrangements in response to external stimuli. Hemagglutinin, a viral fusion protein
found on the surface of influenza, refolds into an extended conformation at low pH. The
conformational refolding of hemagglutinin results in the fusion peptide becoming
exposed and likely inserting into the target membrane leading to membrane fusion.
Identification of mutations that stabilize or destabilize the neutral pH structure of
hemagglutinin may lead to better understanding of the structure-function relationship of
the protein. Previous directed evolution work produced a series of mutants that refolded
at a different pH than wild-type fowl-plague virus (FPV) HA. The mutants were analyzed
to identify individual residues that were responsible for the altered conformational
stability. The results indicate that the HA1 head group is vitally important in controlling
acid-induced refolding as four out of the six mutations that altered stability were found in
the HA1 headgroup.
The entire ligand binding site for the lymphocyte function-associated antigen-1
(LFA-1 integrin αLβ2) is contained solely within the inserted (I) domain of the α chain of
the integrin. Affinity for the I domain ligand, ICAM-1, which is overexpressed on
inflamed endothelium is allosterically regulated. Downward displacement of the Cterminal α7 helix causes a disruption in the hydrophobic core of the I domain leading to
rearrangement of residues in the metal ion-dependent adhesion site (MIDAS) resulting
in higher affinity. This allosteric rearrangement was exploited to create a chimeric
fusion protein whose affinity for ICAM-1 was regulated by the presence of an
exogenous peptide. Directed evolution was used to improve the functional activity of
this protein switch and to alter the specificity of the activating peptide
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Both proteins, hemagglutinin and the I domain-calmodulin fusion, represent the
importance of conformational changes in controlling protein function. The ability to
manipulate these changes underscores the power of protein engineering and directed
evolution and can lead to the development of complex biomolecules that can be used in
a variety of applications from biosensing to molecular imaging to drug delivery.
5.2 Engineering Protein Switches
The first aim of this dissertation was to engineer improved molecular switches via
circular permutation. Circular permutation has proven a successful approach for
identifying non-obvious sites for domain insertion to more closely couple the functions of
two disparate protein domains in order to effect greater switch activity. Circular
permutation was used to identify sites within the I domain amenable to domain insertion
by sorting for permuted I domains that retained ICAM-1 binding. A population of
circularly permuted I domains was enriched 17-fold for ICAM-1 binders; however, upon
sequence analysis of clones from this population it was apparent that the only site that
was tolerant of new termini was the allosteric region of the I domain. This information
was used to then focus mutagenesis of a subsequent library on the allosteric region of
protein. By focusing the mutagenesis efforts in this region, along with alternating
between positive and negative sorts, the likelihood of identifying mutations that would
be beneficial to improved switch activity was increased. Mutations identified through
cell sorting were combined to determine a complementary set of amino acid changes
that simultaneously improved the off-state of the switch (i.e., minimal ICAM-1 binding in
the presence of the scrambled peptide) and retained or improved the on-state of the
protein (i.e., retained or improved ICAM-1 affinity in the presence of smMLCK peptide).
Mutant, M12, emerged for the directed evolution studies with a near twenty-fold
increase in switch activity. This mutant contained a total of three mutations: L289R,
Y307S, and M337V. The most significant being L289R, helping to stabilize the off-state
of the switch. This mutation results in a salt bridge between the β6-α7 loop and the α7
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helix stabilizing the closed conformation of the I domain until a sufficient enough strain
on the α7 helix, resulting from the binding of smMLCK peptide, breaks this interaction
allowing the I domain to bind ICAM-1 with higher affinity. The other two mutations,
Y307S and M337V, likely contribute to greater conformational flexibility (Y307S) and
increased peptide affinity (M337V).
Demonstrating that both domains of an adhesive protein switch can be
engineered expands the potential of this technology. To that end, we demonstrated that
it was possible to alter the specificity of the peptide to which the switch responds. In the
original and improved constructs, smMLCK peptide acted as the agonist peptide
increasing the I domain affinity for ICAM when the peptide was present. Conversely,
when a scrambled version of the smMLCK peptide was present as a negative control,
the I domain remained in a lower affinity state as the EF hands did not bind the peptide
therefore not inducing the high affinity state. As a proof of concept, directed evolution
was used to change the protein switch‟s response to each of these peptides. In
essence, smMLCK peptide now served as a negative control while the scrambled
peptide served as the agonist peptide inducing a higher affinity conformation of I
domain. Directed evolution was used to isolate a number of different mutants that
responded specifically to scrambled peptide.
5.3 Characterizing Protein Switches
The two proteins in this study required various degrees of characterization.
Hemagglutinin, which undergoes an acid-induced conformational switch, had individual
point mutants introduced to identify residues that were responsible for the altered pH
stabilities. Fifteen of the sixteen mutations found through a previous directed evolution
experiment and characterized in this work had never before been found highlighting the
power of directed evolution studies. More importantly to this work, examination of these
individual residues highlighted the importance of the HA1 headgroup in pH sensing and
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conformational stability. Four mutations (I96M, G237R, W243S, and G365C) were
found to destabilize the HA trimer with three of the four residues being located in the
HA1 headgroup. Additionally, W243S and G365C are highly conserved residues across
all HA subtypes. Two mutations (D247N and S429P) stabilizing the neutral pH structure
were also identified. Again, one of the mutations, D247N, was found at the interface
between two HA1 headgroups and is believed to alleviate the native charge repulsion
present between D247 and E414. The majority of these pH-sensing residues are
located in the HA1 headgroup signifying its importance in the conformational switching
activity of hemagglutinin. The majority of previously identified pH sensing residues have
been located in the HA2 domain of hemagglutinin, implicating this subunit as the
critically involved in pH sensing. Our results indicate that it is very likely that the HA1
headgroup controls pH sensing and thus triggers HA refolding since it needs to be
displaced from its neutral location in order for HA2 to refold to its extended low pH
conformation.
5.3 Recommendations
5.3.1 Characterization of altered specificity switches
While we have shown the ability to alter the peptide specificity of the EF3 and
EF4 hands of our chimeric protein switch further engineering should be pursued to
improve the activity of the switch. While decreased affinity for ICAM-1 wasn‟t
unexpected, likely due to low affinity binding of the calmodulin domains to scrambled
peptide, it would need to be improved to fully exhibit the potential of engineering a
chimeric, adhesive switch. Further mutagenesis using a loop shuffling approach, similar
to that used to engineer high affinity fibronectin type III (Fn3) binders to lysozyme,118
would take advantage of the mutations already found to be beneficial while expanding
the diversity to identify mutants with higher affinity for scrambled peptide thus improving
the switch activity. If loop shuffling failed to improve the altered peptide specificity
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switches a true DNA shuffling approach, where the gene is randomly fragmented, could
then be undertaken to improve the new generation of switches. Following identification
of an improved, scrambled peptide specific switch, site-directed mutagenesis could be
used to try and gain further insight into the new binding mechanism. Finally, binding
kinetics using soluble proteins could be used for characterization consistent with
previously developed switch mutants in our lab.
5.3.2 Crystal structure of the protein switch
Structural determination of wild-type switch, switch M12 and possibly an altered
peptide specificity switch could greatly benefit this work. While it would be an arduous
process and would require collaboration with another lab, structures of these switches in
both the bound and unbound states would provide the final atomic details and complete
our understanding of how these switches are functioning. Specifically, a better
understanding of how peptide binding gets allosterically translated to the MIDAS to alter
ICAM-1 binding could be discovered. Both x-ray crystallography and NMR would need
to be used to resolve the actual structure in detail and to gain insight into the dynamics
of the switch upon peptide binding.
5.3.3 Expansion of Protein switch work
Engineering an adhesive protein switch that has essentially two orthogonal states
dependent upon the presence of peptide is a not only a significant achievement but also
unique in the approach. To date, the vast majority of protein switches have been
developed to respond to small ligands (e.g., sugars, ions, light, etc.)17; 18; 19; 97; 119
making their use in a therapeutic application in the near future unlikely. Given that the I
domain of LFA-1 is already critical to the inflammatory cascade, demonstrating the
ability to engineer clinically relevant domains as fusions to the I domain to effect control
of ICAM-1 binding would make this approach very attractive for a number of different
applications. Previously, the αL I domain has been conjugated to the surface of
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nanoparticles for targeted delivery of drug and gene therapies to cells over expressing
ICAM-1 both in vitro and in vivo.25; 26; 27 These molecules use previously engineered
high affinity I domain28 to selectively target ICAM-1 making these nanoparticles highly
efficient at targeting tumors where drug delivery by the permeability and retention (EPR)
effect is less efficient. Designing a protein switch where I domain affinity is regulated by
the presence of exogenous peptide would provide an additional layer of specificity in
targeted imaging and delivery systems. Further engineering of peptide specificity would
enhance the targeting capabilities.

5.6 Conclusions
This dissertation undertook the task of engineering and characterizing two
distinct proteins both of which had distinct structural rearrangements, or switching
actions, which contributed to their function. Understanding and manipulating protein
switches is a worthwhile endeavor for several reasons. Manipulation of protein
conformational changes can lead to a greater understanding of the structure-function
relationship of a protein and the identification of key structural features can provide a
good starting point for future protein engineering work. Also, the ability to combine two
distinct proteins and couple their functions holds tremendous potential for the design of
future biomaterials. The number of strategies or applications where the coupling of two or
more proteins could be exploited for more precise control of an enzymatic reaction or protein
interaction is likely limitless making engineering of protein switches a powerful tool.
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Appendix 1. Site directed mutagenesis of HA primers

Table A1. 1 Primers for sited directed mutagenesis of FPV HA
Primer

Sequence

I96M

5‟ – ATGCGACCAATTTCTAGAATTTTCAGCTAGTCTAATAATCGAGAGACGAG –
3‟
5‟ - CTCGTCTCTCGATTATTAGACTAGCTGAAAATTCTAGAAATTGGTCGCAT –
3‟
5‟ – TCAGCTGATCTAATAATGGAGAGACGAGAAGGA – 3‟

I96M_anti

5‟ – TCCTTCTCGTCTCTCCATTATTAGATCAGCTGA – 3‟

G142D

5‟ – GGAATAAGGACCAACGACACAACTAGTGCATGT – 3‟

G142D_anti

5‟ – ACATGCACTAGTTGTGTCGTTGGTCCTTATTCC – 3‟

FPV HA Y155F

5‟ – GGGTCTTCATTCTTTGCAGAAATGGAGTGG – 3‟

FPV HA Y155F_anti

5‟ – CCACTCCATTTCTGCAAAGAATGAAGACCC – 3‟

D166G

5‟ – CTGTCAAATACAGGCAATGCTTCTTTCCCA – 3‟

D166G_anti

5‟ – TGGGAAAGAAGCATTGCCTGTATTTGACAG – 3‟

FPV HA A168V

5‟ – GACAATACAGACAATGTTTCTTTCCCACAA – 3‟

FPV HA A168V_anti

5‟ – TTGTGGGAAAGAAACATTGTCTGTATTGTC – 3‟

V188G

5‟ – GAATCAGCTCTGATAGGATGGGGAATCCACCAT – 3‟

D93S
D93S_antisense
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Table A1.1 Continued
Primer

Sequence

V188G_anti

5‟ – ATGGTGGATTCCCCATCCTATCAGAGCTGATTC – 3‟

Y218H

5‟ – GGGAGTTCCAAACATCATCAATCTTTTGTG – 3‟

Y218H_anti

5‟ – CACAAAAGATTGATGATGTTTGGAACTCCC – 3‟

D240Y

5‟ – GCCAGAGCGGACGGATTTATTTTCATTGGTTGATCT – 3‟

D240Y_antisense

G237R

5‟ – AGATCAACCAATGAAAATAAATCCGTCCGCTCTGGC – 3‟
5‟ – GATTGATTTTCATTGGTTGATCTTGAATCCCAATGATACAGTTACTTTTAG –
3‟
5‟ – CTAAAAGTAACTGTATCATTGGGATTCAAGATCAACCAATGAAAATCAATC –
3‟
5‟ – AATGGCCAGTCCCGACGGATTGATTTTCAT – 3‟

G237R_anti

5‟ – ATGAAAATCAATCCGTCGGGACTGGCCATT – 3‟

W243S forward

5‟ – CGGATTGATTTTCATTCGTTGATCTTGGATCCC – 3‟

W243S reverse

5‟ – GGGATCCAAGATCAACGAATGAAAATCAATCCG – 3‟

G365C

5‟ – GAAGAAGACTTGTGGTACTGTTTCAGGCATCAGAATG – 3‟

G365C_antisense

5‟ – CATTCTGATGCCTGAAACAGTACCACAAGTCTTCTTC – 3‟

L407A

5‟ – ACCAACCAGCAATTTGAGGCAATAGATAATGAA – 3‟

L407A_anti

5‟ – TTCATTATCTATTGCCTCAAATTGCTGGTTGGT – 3‟

D247N
D247N_anti
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Table A1.1 Continued
Primer

Sequenc

S429P

5‟ – AACTGGACCAAAGACCCCATCACAGAAGTATGG – 3‟

S429P_anti

5‟ – CCATACTTCTGTGATGGGGTCTTTGGTCCAGTT – 3‟

E462Q

5‟ – TCAGAGATGAACAGGCTGTATCAGCGAGTGAGG – 3‟

E462Q_antisense

5‟ – CCTCACTCGCTGATACAGCCTGTTCATCTCTGA – 3‟
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Appendix 2. pH transition curves for pH 4.8 selected mutants

Figure A2. 1 pH transition curves for pH 4.8 selected mutants
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Appendix 3. pH transition curves for pH 5.6 selected mutants

Figure A3. 1 pH transition curves for pH 5.6 selected mutants.
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Appendix 4. pH transition curves for pH 6.0 selected mutants

Figure A4. 1 pH transition curves for pH 6.0 selected mutants
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Appendix 5. Yeast surface display construct

Figure A5. 1 Yeast surface display construct showing a protein switch. Proteins are
displayed as C-terminal fusions to Aga2p with two epitope tags (HA and c-myc) on
either side of the protein of interest. Commercial antibodies against either epitope can
be used to assay surface expression level. For ICAM binding, an ICAM-Fc fusion (R&D
Systems) was precomplexed with an anti-Fc AlexaFluor 647 antibody (Jackson
ImmunoResearch) and the precomplexed ICAM/Anti-Fc AF647 was used to assess I
domain or switch affinity.
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Appendix 6. Circular permutation primers

Table A6. 3 Primers for addition of AfeI restriction site
Primer Name

Sequence

AfeI - rc A4 for

5’ - GCTAGCAGCGCTTGTATCAAGGGCAACGTAG – 3’

AfeI – rc A4 rev

5’ – GGATCCAGCGCTGCCCTCAATGACATAGATCT – 3’

Note: Primers for insertion of AfeI restriction site for blunt-end ligation into pCT302 to
create pCT-JVP

Table A6. 4 Primers for the addition of GGGSG linker for circular permutation
Primer Name

Sequence

N-Id 6 Linker Cp

5’ – GGATCCGGTGGTTGTATCAAGGGCAACGTA – 3’

C-Id 5&6 Linker Cp

5’ – GGATCCACCACCGCCCTCAATGACATA – 3’

Note: Primers used to add short Gly-Ser linker when circularized with BamHI
(GGATCC) restriction enzyme.
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Appendix 7. Circular permutation of I domain

1

2

3

4

5

6

7

Figure A7. 1 Circular permutation of I domain. Lane 1: 1 kb+ DNA ladder, lane 2:
linearized I domain, lane3: circularly ligated I domain, lane 4: ExoIII digested ligation,
lane 5: DNaseI digested I domain, lane 6: empty, lane 7: T4 polymerase/ligase repair.
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Appendix 8. pCT Switch plasmid

5’ -

- 3’

Figure A8. 1 pCT302 showing the switch gene located between NheI and BamHI
restriction sites.
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Appendix 9. Two color flow cytometry plots of engineered switches.

Figure A9. 1 Two color flow cytometry plots of engineered switches. In all plots,
populations in blue represent switches that were incubated with scrambled peptide and
populations shown in red represent switches incubated with smMLCK peptide. The
vertical axis represents the amount of surface expressed protein and the horizontal axis
represents the amount of bound ICAM-1. Each dot represents an individual cell. Cells
located above the horizontal gate are considered to contain full length protein on the
yeast surface and anything to the right of the vertical gate represents cells with bound
ICAM-1.
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Figure A9. 2 Continued
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Figure A9.1 Continued
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Appendix 10. Representative sensorgrams for I domain/EF hands switches.

Figure A10. 1 Representative sensorgram of a first generation I domain/EF hands
switch. Sensorgrams were generated using a Biacore 3000 where ICAM-1-Fc was
immobilized on a CM5 sensor chip using amine coupling. First generation switches
(SW1 and SW9) were incubated for at least 1 hour with either smMLCK peptide or
scrambled peptide and then injected. Switches were allowed to associate for four
minutes followed by a four minute dissociation phase.
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